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Résumé                                                              
 
L’Insulin-like growth factor-1 (IGF-1) est un peptide vasoconstricteur qui joue un 
rôle proéminent dans la progression des maladies cardiovasculaires, grâce à la génération 
d'espèces réactives de l'oxygène (ERO), ainsi que par l'hyperactivation des voies de 
signalisation qui promeuvent la croissance et l'expression aberrante des gènes. Les 
histones désacétylases (HDACs), par leur aptitude à modifier le statut d'acétylation des 
résidus lysine dans les protéines d'histones et non-histones, régulent la transcription des 
gènes. Des études récentes ont montré qu'une activation accrue des HDACs, notamment 
HDAC5, est associée à des troubles vasculaires tels que l'athérosclérose. Cependant, le 
rôle de l'IGF-1 dans l'activation des HDACs par phosphorylation demeure mal 
caractérisé. Donc, dans les études présentes, on a examiné l’effet de l’IGF-1 sur la 
phosphorylation de HDAC5 dans les cellules musculaires lisses vasculaires (CMLV) de 
type A10 et on a identifié les voies de signalisation impliquées dans ce processus. Le 
traitement des CMLV avec l’IGF-1 a augmenté la phosphorylation de HDAC5 sur la 
serine 498 de manière temps- et dose-dépendante. La pré-incubation des cellules avec 
l’AG1024, un inhibiteur pharmacologique du récepteur membranaire à l’IGF-1, a 
significativement atténué la phosphorylation d’HDAC5 induite par l'IGF-1. Par contre, le 
prétraitement avec l’AG1478, un inhibiteur du récepteur du facteur de croissance 
épidermique, n'a pas eu d'effet significatif sur les niveaux de phosphorylation d’HDAC5. 
En outre, le blocage pharmacologique de la voie MAP kinase avec divers inhibiteurs 
(PD98059, UO126, SP600125 et SB203580) n’a pas abrogé la phosphorylation 
d’HDAC5, cependant les inhibiteurs de la voie protéine kinase B (PKB)/PI3-K, SC-66 et 
wortmannine respectivement,  ont complètement aboli la phosphorylation d’HDAC5 
induite par l’IGF-1. Ces données ont été confirmées par des expériences 
d’immunofluorescence et de silençage génique de PKB par interférence d’ARN. En 
outre, le prétraitement des cellules avec le diphénylèneiodonium (DPI) et l’apocynine, 
deux inhibiteurs de la NAD(P)H oxydase, ainsi que l'antioxydant N-acétyl-cystéine 
(NAC), a atténué la phosphorylation de HDAC5 et de PKB par l’IGF-1. De plus, le 
silençage génique de Nox4, la principale NAD(P)H oxydase des CMLV, a atténué la 
phosphorylation d’HDAC5 induite par l’IGF-1. De plus, l’utilisation des techniques 
d’extraction nucléaire a indiqué que le SC-66 et le DPI inhibent l’exportation nucléaire 
de HDAC5 induit par IGF-1. En résumé, ces données suggèrent que l'IGF-1 induit la 
phosphorylation et l’exportation nucléaire de HDAC5 de façon ERO et PKB-dépendante 
dans les CMLV.  
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Abstract 
 
Insulin-like growth factor 1 (IGF-1), a potent mitogenic and vasoactive factor, has 
been shown to play a role in the development of cardiovascular diseases. This occurs 
through the generation of reactive oxygen species (ROS) as well as through the 
hyperactivation of mitogenic and growth promoting signaling pathways and the 
subsequent alteration in gene expression. Histone deacetylases (HDACs), by their ability 
to modify the acetylation status of the lysine residues in histone and non-histone proteins, 
regulate gene transcription. Recent studies have demonstrated that a heightened 
activation of HDACs, notably HDAC5, is associated with vascular disorders such as 
atherosclerosis. However, a role of IGF-1 in HDAC phosphorylation and activation has 
not been investigated. Therefore, in the present studies, we examined the effect of IGF-1 
on the phosphorylation of HDAC5 in vascular smooth muscle cells (VSMCs) and 
identified the signaling pathways involved in this process. Treatment of A10 VSMCs 
with IGF-1 enhanced the phosphorylation of HDAC5 at serine 498 in a time and dose-
dependent fashion. Pretreatment of cells with AG1024, a selective pharmacological 
inhibitor of IGF-1R, significantly inhibited IGF-1-induced HDAC5 phosphorylation in 
A10 VSMCs whereas AG1478, a selective inhibitor of epidermal growth factor receptor 
(EGFR), did not have an inhibitory effect on the levels of phospho-HDAC5. 
Pharmacological blockade of the MAPK pathway with PD98059, UO126, SP600125 and 
SB203580 had no effect on HDAC5 phosphorylation, whereas inhibitors of the PI3K/ 
PKB pathways, wortmannin and SC-66 respectively, almost completely attenuated IGF-
1-induced HDAC5 phosphorylation. These findings were confirmed by 
immunofluorescence localization of phospho-HDAC5 and by siRNA-induced silencing 
of PKB. In addition, pretreatment of A10 VSMCs with Diphenyleneiodonium (DPI) and 
apocynin, two NAD(P)H oxidase inhibitors, as well as the antioxidant N-Acetyl-Cysteine 
(NAC), resulted in an attenuation of IGF-1-induced HDAC5 and PKB phosphorylation. 
Furthermore, siRNA-induced silencing of Nox4, the main NADPH oxidase expressed in 
VSMC, inhibited IGF-1 induced HDAC5 phosphorylation. Moreover, IGF-1-induced 
phosphorylation of HDAC5 resulted in its nuclear export, which was reversed by 
blockade of PKB by SC-66 or NAD(P)H oxidase inhibition by DPI. In summary, these 
data demonstrate that IGF-1 induces the phosphorylation and nuclear export of HDAC5 
in a Nox4-derived ROS- and PKB-dependent fashion in VSMCs. 
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Chapter 1 
 
Introduction 
 
 
 
 
 
 
 
1 
 
 
 
According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are 
the leading causes of death worldwide, with an estimated 17.5 million CVD-related deaths in 
2012 (1). CVDs are associated with vascular remodeling characterized by increased vascular 
resistance (2). Abnormal migration, growth and proliferation of vascular smooth muscle cells 
(VSMCs) have been implicated in vascular remodeling and vascular diseases such as 
atherosclerosis, hypertension, intimal hyperplasia and restenosis (3, 4, 5). Vasoactive peptides 
and growth factors, such as insulin-like growth factor 1 (IGF-1), have been suggested to play a 
key role in vascular remodeling by promoting VSMC proliferation, migration and hypertrophy 
(6, 7). Studies have suggested that IGF-1, a potent mitogenic and vasoactive factor (8), 
contributes to the aberrant phenotype of VSMCs through the hyperactivation of growth 
promoting signaling pathways and the subsequent alteration in gene expression (9). Histone 
deacetylases (HDACs), by their ability to modify the acetylation status of lysine residues in 
histone and non-histone proteins, have been suggested to be involved in epigenetic regulation of 
gene transcription (10) and recent studies have suggested that HDACs may be involved in 
vascular remodelling events leading to CVDs via their effects on genes implicated in cell growth, 
proliferation and migration (11). Epigenetic modifications, such as acetylation, have emerged as 
important mechanisms that modulate gene expression without changing the DNA sequence and 
thus provide rapid and reversible regulation of many genes (12).  The following sections provide 
a brief overview on the structure and function of IGFs and HDACs, as well IGF-1’s mechanism 
of action, with particular interest to its role in the cardiovascular system.  
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1. General properties of IGFs 
Insulin-like growth factors (IGFs) belong to a family of polypeptide hormones, also 
called somatomedins (13). Prior to this nomenclature, IGFs were first termed sulfation factors 
because of their ability to stimulate the sulfation of proteoglycans that are present in cartilage 
(14). To date, the IGF system consists of IGF-1 and IGF-2, two cell surface receptors (IGF1R 
and IGF2R) and IGFBP-1 to IGFBP-6, six high affinity IGF-binding proteins, as well as IGFBP 
degrading enzymes. The IGF system has been shown to be involved in the regulation of 
important cellular and physiological processes, including development, growth, cell regulation 
and metabolism (15).  
 
1.1 Structural features of IGFs 
As previously mentioned, there exist two IGFs, IGF-1 and IGF-2, and their structural 
features can be examined at the gene as well as the protein level.  
 
             1.1A Structural features of IGF-1 
The IGF-1 gene is located on human chromosome 12 (16) and the gene sequence 
contains six exons and five introns spanning 80kb of chromosomal DNA (17). Exons 3 and 4 
encode a portion of the N-terminal signal sequence, the complete sequence of the mature protein 
and a portion of the C terminus. Exons 1, 2, 5 or 6 can be alternatively spliced leading to four 
splice variants or mRNA subtypes containing differences in the 5’ and 3’ untranslated regions 
(UTR) (17). The IGF-1 gene sequence has been shown to be highly conserved amongst species 
(18). Two promoter regions in the IGF-1 gene sequence have been identified to date and are  
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termed P1 and P2. P1 and P2 are located upstream of exon 1 and exon 2, respectively, and do not 
contain TATA and CAAT elements (19).  
 
The IGF-1 protein is a single chain polypeptide composed of 70 amino acid residues 
having a molecular weight of 7.6 kDa (20). The IGF-1 sequence is known for a number of 
different species and is shown to be highly conserved (18). It has a 70% sequence homology 
with IGF-2 and a 50% sequence homology with proinsulin. IGF-1 protein is comprised of 4 
domains, with domain A and B having the most homology with insulin (60 to 70% similarity) 
(20). The A domain, which is made up of 21 residues, contains alpha helix 2 and alpha helix 3 
joined by a loop. IGF-1’s B domain consists of 29 residues and contains an extended N-terminal 
coil followed by a tight turn and a central alpha helix 1, forming a hydrophobic core (20, 21). 
The C and D domains, 12 and 8 amino acids respectively, have no homology with proinsulin and 
form the carboxy terminus of the protein (22). The three dimensional structure of IGF-1, through 
nuclear magnetic resonance (NMR) and X-ray crystallography methods, has been reported by 
several groups (20, 22). Figure 1 depicts the IGF-1 mRNA transcript and protein structure.  
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Figure 1: Schematic illustration of the IGF-1 mRNA transcript and protein structure. The 
mRNA transcript possesses a 5’UTR and leader sequence derived primarily from exons 1 
or 2 depending on the mRNA subtype. A 3’UTR is derived from exons 5 and 6 and is also 
dependent on mRNA subtype. Exons 3 and 4 encode B, C, A, D and E domains which are 
translated into pre-protein. Proteolytic cleavage of the C-terminal E domain results in the 
formation of a mature protein. The protein contains three disulfide bridges (17, 20-22).  
 
1.1B Structural features of IGF-2 
 The IGF-2 gene is found on chromosome 11. IGF-2 preprohormone consists of 180 
amino acids and contains a carboxy-terminal peptide of 89 amino acids and a signal peptide of 
24 amino acids, both of which are cleaved following translation to yield a 67-amino acid plasma 
protein (23).  
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IGF-2 is a single chain polypeptide hormone composed of 67 amino acids with a 
molecular weight of 7.4kDa (22). Like IGF-1, IGF-2 contains A, B, C and D domains. The A 
domain is comprised of 21 residues, an alpha helix 2 (Glu44-Phe48) and an alpha helix 3 (Ala54-
Tyr59). Its B domain has 29 residues and a central alpha helix 1 (Gly10-Val20). IGF-2’s C and 
D domains have the same properties as IGF-1’s C and D domains (21, 22).  
 
1.2 Regulation of IGF-1 levels 
 During prenatal and postnatal growth and development, serum IGF-1 levels vary from 
20ng/mL in fetal stages to 200 ng/mL after birth (24). IGF-1 concentration can be regulated in a 
number of ways at different functional levels. Namely, at the level of IGF-1 synthesis, at the 
post-translational stage, and by interactions with insulin-like growth factor-binding proteins 
(IGFBPs).  
 
1.2A Regulation of IGF-1 at the level of synthesis 
IGF-1 is predominantly synthesized in the liver and its plasma concentration is regulated 
by liver growth hormone (GH) depending on nutritional status. Plasma IGF-1 levels are 
maintained at a normal level through a negative-feedback mechanism that suppresses GH 
synthesis in the pituitary gland when IGF-1 levels are high (25).  In addition to synthesis in the 
liver, IGF-1 can also be synthesized in many peripheral tissues, including skeletal muscle, bone, 
and cartilage, enabling it to act locally as an autocrine/paracrine factor or more distantly as an 
endocrine factor (26). Furthermore, IGF-1 has also been shown to be synthesized and secreted by 
vascular cells. Studies indicate the existence of three IGF-1 mRNA transcripts localized in the  
smooth muscle layer of the adult rat aorta and two IGF-1 mRNA transcripts in aortic endothelial 
cells (27).                                                                                                                                          6 
 
 
 
Three IGF-1 transcription factors (TFs) have been identified, CAAT-box/enhancer 
binding protein (C/EBP), hepatocyte nuclear factor-1 (HNF-1) and HNF-3, and they bind to six 
binding sites within the P1 (expressed in all tissues) and P2 (expressed primarily in the liver) 
promoter regions (28). Once transcription is initiated at these promoter regions, a pre-pro-IGF-1 
precursor protein is formed, which contains a signal peptide, a signal cleavage site, the mature 
IGF-1, a pro-protein convertase cleavage site and a C-terminal E-peptide extension (29). During 
translation, which occurs in the endoplasmic reticulum (ER), the N-terminal signal sequence is 
cleaved and the pro-IGF-1 polypeptide (mature IGF-1 and E-peptide) is formed.  
 
A number of factors have been found to regulate the bioactive levels of IGF-1. For 
example, insulin has been shown to increase liver IGF-1 transcription in vivo (30) and in primary 
hepatocyte cultures (31). GH also has been found to increase IGF-1 mRNA in primary 
hepatocytes (32) and in the liver (in vivo) (33). Furthermore, glucagon (34) and the thyroid 
derived hormone, triiodothyronine (T3) (35), have been shown to increase IGF-1 mRNA in 
primary hepatocytes. In addition to these hormones, genetic factors and age are also important 
determinants in controlling the variability in IGF-1 levels (25).  
 
1.2B Regulation of IGF-1 at the post-translational stage 
Prior to secretion, the pro-IGF-1 polypeptide can undergo various post-translational 
modifications. It can undergo intracellular protease cleavage, which disconnects the mature IGF-
1 protein from the E-peptide. Additionally, it can be secreted without cleavage or it may be 
subjected to E-peptide N-glycosylation and then be secreted. Thus, there are three resulting 
forms of IGF-1: mature IGF-1, glycosylated-pro-IGF-1 and nonglycosylated-pro-IGF-1 (36).  
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1.2C Regulation of IGF-1 through IGFBP interaction 
Following synthesis and release, IGF-1 can be found in a free form (2%) or bound to 
IGFBPs (98%) (37). IGFBPs, which regulate the level of free IGFs in circulation, are composed 
of a family of six proteins (IGFBP-1-6) that bind to IGFs with high affinity and specificity and a 
family of IGFBP-related proteins (IGFBP-rPs), which are structurally similar to the IGFBPs but 
bind IGFs with much lower affinity (38).  
 
IGFBPs were initially discovered while purifying IGF-1 from serum (39). To date, all six 
members of the IGFBP family have been cloned and their complete sequences have been 
elucidated (40). IGFBPs have a highly conserved structure consisting of three domains: an N-
terminal and a C terminal domain, which are both cysteine rich, and a highly variable central 
domain. The N- and C-terminal domains mediate IGF-binding, whereas the central domain 
differs between all IGFBPs and serves as a hinge between the N- and C-terminal domains (41). 
Post-translational IGFBP modifications, such as proteolysis, phosphorylation and glycosylation, 
occur in the central domain and have the ability to alter IGF-binding affinity (42).  
 
IGFBP-3 is the most common IGF binding protein in the blood stream followed by 
IGFBP-2, which is produced in the liver. Most of the circulating IGF-1 and IGF-2 are associated 
with a high molecular weight complex (~150  kDa) consisting of IGFBP-3 and the acid labile 
subunit (ALS) (43). Following separation from the ternary complex, the binary complexes of 
IGFBP-IGF are removed from the circulation and cross the endothelium to reach their target 
tissues and to interact with cell surface receptors (43). In addition to transporting IGFs, IGFBPs 
can protect IGFs from degradation, thus prolonging their half-life. Furthermore, IGFBPs can act  
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as promoters by promoting IGF interaction with their receptor, as well as inhibitors by 
sequestering IGF from its receptor, as the IGFBPs have a higher affinity for the IGFs than the 
receptors (44).  
 
IGFBP action is controlled by IGFBP proteases, which belong to a superfamily of 
proteases with high-affinity for IGFBPs. These proteases are key modulators of the levels of 
IGFBPs and ultimately regulate the bioactivity and downstream actions of IGFs (45). Matrix 
metalloproteinases (MMPs), which degrade several extracellular matrix molecules including 
collagens, elastins and proteoglycans, are also known to be active against IGFBPs (46).  
 
2. Functional features of IGF-1 
 To carry out their biological actions, including regulation of development, growth and 
metabolism, IGFs interact with IGF receptors. IGF-1 exerts its physiological actions through its 
interaction with IGF-1R, a high-affinity receptor specific to IGF-1. IGF-1 has also been shown to 
bind to IGF-2R with low affinity, though IGF-2 is the high affinity ligand for IGF-2R (21). 
Additionally, there is high homology between IGF-1R and the insulin receptor and activation of 
these receptors triggers similar downstream signaling pathways. Insulin and IGF-1 demonstrate 
high affinity binding with their specific receptors, however insulin can also bind and activate 
IGF-1R. Therefore, though IGF-1 is the main activator of IGF-1R, insulin may potentially 
contribute to its activation as well (47). 
 
2.1  IGF-1 receptor                                                                                                                   9 
 
 
 
Human IGF-1R is a ubiquitously expressed product of a single-copy gene located on 
chromosome 15 (47). In terms of its structure, IGF-1R is a heterotetramer consisting of two 
extracellular ligand binding α-subunits that are linked by disulfide bonds to each other and to two 
transmembrane β-subunits that contain intrinsic tyrosine kinase activity, which is believed to be 
essential for most of the receptor’s biological effects (47).                                                              
 
IGF-1R is first synthesized as a single polypeptide chain, known as the IGF-1 
preproreceptor, and is then cleaved post-translationally to form a proreceptor. The proreceptor is 
then glycosylated, folded and dimerized by calnexin and calreticulin (48), two chaperones, and 
finally it is transported to the Golgi apparatus to yield the mature IGF-1 receptor. Mature IGF-1R 
bears strong similarities in biochemical structure to the insulin receptor (IR) (49). IGF-1R is 
composed of three domains: an N-terminal extracellular hormone-binding domain, a 
transmembrane region, and a C-terminal intracellular domain with intrinsic kinase activity and 
regulatory residues (50). IGF-1R’s α-subunit and 194 residues of the β-subunit are situated in the 
N-terminal and this region includes 11 potential N-linked glycosylation sites, as well as two 
homologous leucine-rich domains separated by a cysteine-rich region (51). The rest of the β-
subunit is composed of the transmembrane region and the C-terminal intracellular domain (52). 
The C-terminal intracellular domain consists of a tyrosine kinase catalytic domain that is flanked 
by two regulatory regions, which contribute to IGF-1R activation. The first regulatory region is a 
juxtamembrane site, which is involved in the docking of insulin receptor substrates (IRS) and Src 
homology collagen (Shc) and the internalization of the IGF-1R (53). The second regulatory 
region is a 108-residue carboxyterminal tail that contains phosphotyrosine binding sites (54). 
Figure 2 depicts IGF-1R’s mRNA structure, its processing and its protein structure.                  10 
 
 
 
 
Figure 2: IGF-1R mRNA structure, processing and protein structure. IGF-1R’s functional 
domains are indicated above corresponding to numbered exons. Upon translation, the 
prepeptide is processed by means of glycosylation, proteolytic cleavage and addition of 
disulphide linkages. The α and β subunits are assembled and expressed on the cell 
membrane. The α subunit is exclusively extracellular and the β subunit is primarily 
intracellular, but it also contains a transmembrane region and a small extracellular region 
(47, 50-52).  
 
Once IGF-1 activates IGF-1R, its physiological effects are exerted through multiple 
signaling cascades, such as the mitogen activated protein kinase (MAPK) and the phosphatidyl-
inositol-3-kinase/protein kinase B (PI3-K/PKB) cascades (47, 55, 56). The activation of these 
pathways is implicated in many cellular processes including VSMC growth, proliferation, 
migration and survival (57, 58). In terms of the specific events leading to IGF-1R activation, 
after IGF-1 binds to IGF-1R’s extracellular α-subunit, the receptor undergoes a 
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conformational change, which activates the tyrosine kinase activity of the β-subunit. This then 
leads to the transautophosphorylation of several tyrosine residues in the regulatory domain of the 
β-subunit of IGF-1R (Tyr 1131, 1135 and 1136), resulting in increased receptor tyrosine kinase 
activity (59). IGF-1R’s activated protein tyrosine kinase activity then phosphorylates several 
cytosolic substrates, which include IRS 1-4 and the adaptor protein Shc. These phosphorylated 
cytosolic substrates then serve as docking sites that bind with Src homology 2 (SH2) domain-
containing proteins, such as growth factor receptor-binding protein 2 (Grb-2), the guanine 
nucleotide exchange factor son of sevenless (SOS) and the p85 regulatory subunit of PI3-K (60). 
 
2.2. IGF-2 receptor 
Unlike IGF-1R, IGF-2R, which is also called mannose-6-phosphate receptor, is a cell-
surface receptor with no protein tyrosine kinase activity. IGF-2R is made up of 4 structural 
domains: an amino-terminal signal sequence domain, an extracytoplasmic domain, a 
transmembrane region and a carboxyterminal tail (61). IGF-2R functions in clearing IGF-2 from 
the cell surface by internalization and lysosomal degradation, thereby decreasing IGF-2’s 
mitogenic effects (62). Furthermore, it has been shown that IGF-2R can exist in a cleaved form 
in circulation, therefore enabling it to act as an IGFBP for IGF-2 protein (62).  
 
2.3. IGF-1 signaling  
As previously mentioned, activation of IGF-1R by IGF-1 can activate multiple signaling 
pathways including the MAPK and the PI3-K/PKB cascades.  The activation of these signaling  
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pathways induces different biological actions of IGF-1, including cell growth, migration, and 
survival. In addition to activating growth promoting signaling pathways, IGF-1 has also been 
shown to mediate its downstream effects through reactive oxygen species (ROS), namely 
superoxide and hydrogen peroxide, generation (15, 63, 64). 
 
2.3A IGF-1 signaling and MAPK cascade 
One of the signaling cascades activated by IGF-1 is the MAPK pathway. MAPKs, a 
group of serine-threonine kinases, are classically associated with cell growth, proliferation, 
differentiation and apoptosis, which are all key processes involved in VSMC remodelling (61). 
Five members of the MAPK family have been described in mammalian cells: extracellular signal 
regulated kinases 1 and 2 (ERK1/2), Jun N-terminal kinase 1, 2 and 3 (JNK1/2/3), p38 MAPK, 
ERK5, and ERK7 (65). These MAPKs all follow a similar system of sequential activation by 
several upstream signaling components, in which a stimulus activates a MAPKKK, which will 
then phosphorylate and activate a MAPKK, which will at last phosphorylate Thr and Tyr 
residues in the activation loop of the final effector, MAPK, leading to its activation and hence 
cellular response. For example, ERK1/2 activation by IGF-1 is initiated through the recruitment 
of the Grb-2/SOS complex to phosphorylated IRS or Shc. Subsequently, guanosine diphosphate 
(GDP) is exchanged for guanosine triphosphate (GTP), leading to the activation of Ras, a GTP-
binding protein. This process initiates sequential phosphorylation by recruiting the serine-
threonine kinase Raf to the membrane. This then leads to the activation of MAP kinase kinase 1 
and 2 (MEK1 and MEK2) and ERK1/2 by phosphorylating threonine and tyrosine residues 
within a conserved Thr-Glu-Tyr motif in their activation loop (66, 67). Activation of ERK1/2 can 
lead to the phosphorylation of serine and threonine residues on downstream cytosolic targets of  
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ERK1/2. ERK1/2, along with other MAPK family members, can also be translocated from the 
cytosol to the nucleus where they can phosphorylate and activate several transcription factors, 
such as SRF, ATF2 and Jun, which are implicated in the activation of genes involved in cell 
growth and differentiation (68).  
 
2.3B IGF-1 signaling and PKB pathway 
Another well-known pathway that is triggered by IGF-1R activation in the vascular 
system is the PI3-K/PKB cascade. Similarly to the MAPK cascade, the PI3-K/PKB pathway 
plays a pivotal role in cell migration, differentiation, proliferation and survival (15). 
 
PI3-Ks are grouped into three classes based on their substrate specificity, molecular 
structure and mode of regulation. Class I PI3-Ks generate phosphatidylinositol 3 phosphate 
(PI(3)P), phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2) and phosphatidylinositol 3,4,5-
triphosphate (PI(3,4,5)P3) and are activated by both R-PTK as well as G-protein coupled 
receptors (GPCR). Class II PI3-Ks generate PI(3)P and PI(3,4)P2, and possess a lipid binding 
domain, whereas, class III PI3-Ks only generate PI(3,4,5)P3 (69). Class I PI3-Ks are further 
subdivided into class IA and IB PI3-Ks and are heterodimeric proteins composed of a catalytic 
and regulatory subunit. Class IA proteins consist of a 110 kDa (p110) catalytic subunit and an 
associated 85 kDa (p85) regulatory subunit. Class IA has three isoforms of the catalytic subunit, 
p110α, p110β and p110δ, and several isoforms of the regulatory subunit, p85α, p55α, p50α, p85β 
and p55γ. In contrast to class IA, class IB has only one catalytic member, p110γ, and one form of 
the regulatory subunit, p101. The class IA PI3-Ks are activated by R-PTK, while class IB is 
activated by GPCR (70). 
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The p85 regulatory subunit of PI3-K, which is an SH2 domain-containing protein, 
interacts with phosphorylated IRS and stimulates the activation of p110 (69, 70). Activated PI3-
K catalyzes the conversion of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) to 
phosphatidylinositol 3,4,5-triphosphate (PI(3,4,5)P3), a key signaling molecule and important 
secondary messenger. PI(3,4,5)P3 recruits cytosolic proteins with pleckstrin-homology (PH) 
domains such as the serine/threonine kinase PKB and phosphoinositide-dependent kinase 1 and 2 
(PDK1/2) (71).  
 
Several downstream targets of PI3-K have been documented, the most studied being 
PKB, also known as Akt (a product of akt proto-oncogene). PKB is a 57 kDa serine-threonine 
kinase with three identified isoforms in the mammalian system, PKBα/Akt1, PKBβ/Akt2 and 
PKBγ/Akt3 (72). All isoforms possess an N-terminal pleckstrin homology (PH) domain that 
binds to phospholipids generated by PI3-K, a central catalytic kinase domain with specificity for 
serine or threonine residues on substrate proteins, and a C-terminal regulatory domain containing 
a hydrophobic motif (73). Full activation of PKB is a sequential two-step process where the 
lipid products generated from PI3-K are recognized by the PH domain of PKB, translocating it to 
the plasma membrane, where it then gets phosphorylated on Thr308 by PDK-1 and on Ser473 by 
mTORC2 for its complete activation (74). PKB has numerous downstream targets, such as 
mammalian target of rapamycin (mTOR) (72), glycogen synthase kinase-3 (GSK-3) (75), and 
caspase-9 (76). Figure 3 illustrates IGF-1-mediated activation of the MAPK and PKB cascades.  
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Figure 3: Schematic representation of IGF-1 signaling pathways. IGF-1 functions as a 
high-affinity ligand for IGF-1R in the cellular membrane, leading to autophosphorylation 
of IGF-1R and recruitment of the IRS adaptor proteins. The interaction of IGF-1R with 
the IRS proteins induces the activation of PI3K. PI3K converts PIP2 into the lipid second 
messenger PIP3. PIP3 then activates PDK1 and PDK2, which go on to phosphorylate PKB 
at threonine 308 (Thr308) and serine 473 (Ser473), respectively.  Activated PKB regulates 
downstream signaling molecules leading to cell proliferation and growth. In parallel, the 
activation of the MAPK pathway leads to increased cell survival, growth and cell cycle 
progression. Additionally, IGF-1R activation can lead to increased ROS generation via 
NAD(P)H oxidase activation, triggering the PKB and MAPK pathways (15, 61, 70, 71). 
 
            2.3C IGF-1 signaling and ROS generation 
As indicated in Figure 3, in addition to activating growth promoting signaling pathways, 
IGF-1 has also been shown to mediate its downstream effects through ROS generation (15). ROS 
are very small, rapidly diffusible, highly reactive molecules that take part in physiological 
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 reactions as well as signal transduction, but excessive synthesis of these molecules can 
overcome their antioxidant mechanisms and generate deleterious effects, often resulting in the 
development of CVDs (77). This is in part due to their physicochemical properties which allow 
them to disrupt biological macromolecules such as lipids, DNA, carbohydrates and proteins. 
Hydrogen radicals (OH˙), superoxide anions (O2˙-), hydrogen peroxide (H2O2), reactive nitrogen 
radicals and its derivative peroxynitrite (ONOO-) are amongst the most important ROS. They are 
generated both enzymatically and non-enzymatically by nearly every cell type including VSMCs 
and endothelial cells (77). Studies have illustrated that the major source of ROS in VSMCs is 
NADPH oxidase (Nox), a flavoprotein (63, 64). It has been demonstrated that, in rat aortic 
VSMCs, the main components of the NADPH complex are the membrane-bound subunits of 
Nox and p22phox as well as Rac1, a small Rho-GTPase (63). A range of mediators detected in 
vascular diseases, including IGF-1, have been shown to modify Nox activity, leading to an 
increase in ROS production (63). Nox4 and Nox1 are the predominantly expressed isoforms of 
Nox in rat aortic VSMCs, however studies indicate that IGF-1 regulates the expression of Nox4 
at a post-transcriptional level and, conversely, has little effect on the expression of Nox1 in 
VSMCs (63, 64). Inhibition of Nox4 expression by siRNA technology inhibits IGF-1-induced 
ROS generation in VSMCs. IGF-1-induced ROS generation has been shown to play an important 
role in VSMC proliferation and migration via MMPs, notably MMP-2 and -9 (63).  
 
3. IGF-1 actions in the vasculature  
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IGF-1 exerts various actions in the vasculature. Numerous studies support the notion that  
IGF-1 is a potent mitogen that plays a permissive role in vascular dysfunction due to its pro-
atherogenic properties, which contribute to VSMC proliferation and migration as well as 
neointimal formation (78, 79). Furthermore, IGF-1 has also been shown to promote chemotactic 
macrophage migration (80) and cell adherent molecule expression leading to the development of 
CVDs, such as atherosclerosis (58). On the other hand, IGF-1 has also been suggested to have a 
protective role in the vasculature.  
 
3.1 Protective actions of IGF-1 in the vasculature 
Evidence suggests that IGF-1 serves in endothelial repair and regulation of vascular tone 
under pathological conditions. It has been shown that IGF-1 induces vasorelaxation through the 
upregulation of nitric oxide (NO) production by stimulating inducible NO synthase (iNOS) in 
VSMC as well as through the activation of endothelial NO synthase (eNOS) in endothelial cells 
(ECs) (81). In fact, a study involving IGF-1 supplementation to diabetic patients, characterized 
by impaired vascular tone, resulted in improved vasodilatory responses mainly by increasing 
eNOS activity (58). Furthermore, studies using a pharmacological blocker of NO synthase (N-
nitro-L-arginine methyl ester), suggest that IGF-1 acts on vascular tone by stimulating 
endothelial NO generation (82, 83). Moreover, studies using ECs have demonstrated that IGF-1 
mediates NO production in an eNOS-dependent manner; this process also depends on the 
activation of the PI3-K/PKB pathway involving Ser1177 phosphorylation (58, 84).  
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In addition to its effects on vascular tone, high levels of IGF-1 in the intimal layer could 
potentially act as a potent survival factor preventing apoptosis of VSMCs, which assists in 
maintaining the structural integrity of the fibrous cap. This VSMC accumulation may in turn act 
as a vascular repair mechanism. Therefore, this protective role of IGF-1 may be beneficial for 
stabilization of the atherosclerotic plaque in the early stage of atherosclerosis (85).  
 
Furthermore, IGF-1 has also been shown to exert anti-inflammatory and antioxidant 
properties by modulating cytokine responses and by upregulating eNOS activity. Using an 
ApoE-null mouse model, it was shown that IGF-1 infusion to the aorta reduced macrophage 
infiltration within atherosclerotic lesions, decreased aortic expression of pro-inflammatory 
cytokines and suppressed vascular superoxide levels via an increase in eNOS activity and NO 
bioavailability (86, 87). IGF-1R deficiency in the macrophages of ApoE-null mice was also 
shown to be associated with accelerated atherosclerosis (88). Furthermore, an in vitro study 
using cultured human aortic endothelial cells also found that IGF-1 has potent endothelial 
antioxidant effects. This effect is largely mediated through the upregulation of glutathione 
peroxidase-1 (GPX-1) expression and activity (89).  
 
3.2. IGF-1 and vascular pathophysiology 
In response to vascular injury, VSMCs downregulate the genes necessary for smooth 
muscle contractile function, such as α-smooth muscle actin and smooth muscle myosin heavy 
chain, they increase their proliferation rate and migration capacity, and they actively secrete 
matrix proteins (90). An upregulation of genes associated with the proliferative state, such as  
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KLF4 and PDGFR (91, 92), also occurs. Furthermore, a change in the expression of calcium 
(Ca2+) signaling proteins, such as voltage-gated Ca2+ channels, ryanodine receptors, 
STIM1/Orai1 channels and SERCA pump isoforms (93), is seen in this process, affecting Ca2+ 
excitation-transcription coupling in VSMCs. This state is called the “activated” or “synthetic” 
state. Although the synthetic state is required for vascular development and during vascular 
repair, it plays a pivotal role in the development of multiple smooth muscle diseases, such as 
atherosclerosis and restenosis following angioplasty (94). IGF-1 has been associated with 
mediating the VSMC phenotype switch from the quiescent/contractile state to the 
activated/synthetic state. Therefore, in pathological conditions, for example in the early stage of 
atherosclerotic plaque formation, a decrease in circulating IGF-1 levels could be beneficial (95). 
 
3.2A IGF-1 and atherosclerosis 
Atherosclerosis is an inflammatory process, which occurs when VSMCs proliferate and 
migrate to the intima layer resulting in neointima formation and the subsequent development of 
atherosclerotic lesions (96). IGF-1’s involvement in the pathogenesis of atherosclerosis has been 
supported by several studies, which collectively indicate a marked increase in IGF-1 and IGF-1R  
expression in human atherosclerotic plaques and also demonstrate that IGF-1 is able to stimulate 
VSMC migration and proliferation (97, 98). Studies using various inhibitors have shown that a 
decrease in IGF-1 or IGF-1R signaling in VSMCs is associated with reduced neointimal area 
size, suggesting that IGF-1 possesses a role in promoting vascular hyperplasia. Similarly, 
targeted overexpression of IGF-1 in VSMCs from carotid arteries resulted in an increase in 
neointimal formation (99). Despite the fact that, as mentioned above, studies in animal models 
and human subjects (86-89) have demonstrated IGF-1’s anti-inflammatory effects, there are                                                                                                                                                                                  
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 studies that suggest otherwise. A possible pro-inflammatory role of IGF-1 in early pro-
atherosclerotic lesions was suggested by Che et al by demonstrating that IGF-1 increased basal  
TNF-α mRNA expression and production in cultured bovine endothelial cells (100). Moreover, 
in atherosclerotic macrophages, it has been illustrated that IGF-1 favors excess LDL uptake and 
cholesterol esterification as well as the release of inflammatory cytokines and upregulated 
chemotactic macrophage migration (58, 80).  
 
            3.2B IGF-1 in hypertension 
Several studies have found a link between IGF-1 and hypertension. For example, 
increased IGF-1 mRNA expression has been found in rat models of aorta hypertrophy, urinary 
bladder hypertrophy and portal vein hypertrophy (101). In spontaneously hypertensive rats 
(SHR), increased IGF-1 caused impaired vasorelaxant properties in pre-contracted 
norepinephrine thoracic aortic rings as compared to normotensive (Wistar Kyoto Rats) rings 
(102). Furthermore, a marked increase in arterial pressure was observed in homozygous mice 
containing a site-specific mutation in IGF-1’s exon 3 (103), further implicating IGF-1 in the 
regulation of blood pressure. IGF-1’s involvement in blood pressure regulation was also 
observed by another group who studied liver-specific IGF-1 knockout mice and saw an increase 
in peripheral resistance and systolic blood pressure in these mice (104). Finally, studies 
performed in patients with essential hypertension reported elevated levels of IGF-1, further 
suggesting a role of IGF-1 in hypertension development (98, 105). Despite these discoveries, the 
precise role of IGF-1 in hypertension still remains unclear.  
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HDACs and histone acetyltransferases (HATs) regulate gene expression through the 
removal or addition, respectively, of acetyl groups on lysine residues of core nucleosomal 
histones. Increased histone acetylation attenuates the electrostatic interaction between histones 
and the negatively charged DNA backbone, thereby promoting the unfolding of the histone–
DNA complex. This then enables transcription factors to access their sites of action, modulating 
the transcription of their target genes (106). As described above, IGF-1 participates in the 
progression of vascular remodeling by activating growth promoting and proliferative signaling 
pathways, such as the MAPK and PKB pathways. The activation of these pathways has been 
shown to alter the acetylation of status of histone and non-histone proteins (107) therefore it is 
possible that IGF-1 may contribute to the development of CVDs by modulating the activity of 
HDACs and HATs.  
 
4.1 General overview of histone modifications  
 In eukaryotic cells, to accommodate the large mass of genetic material within the 
nucleus, DNA is packaged into chromatin. Chromatin is composed of a combination of DNA, 
histone proteins and some RNA. Histones can be covalently modified by a variety of processes 
including acetylation, methylation, SUMOylation, ubiquitination and citrullination (108), thereby 
providing a regulatory mechanism for controlling gene expression. These modifications alter the  
structure of the DNA-histone complex, which in turn affects DNA transcription. Each of these 
histone modifications may be involved in epigenetics; however acetylation has been shown to be 
particularly important in CVDs (109). As mentioned above, acetylation of lysine residues 
neutralizes the charge on histones, which increases chromatin accessibility (109). This is  
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achieved by HATs, which attach acetyl groups to conserved lysine residues on histone tails. 
Conversely, HDACs remove these groups and therefore reduce DNA transcription. Several 
studies suggest the involvement of HDACs in vasoactive peptide/growth factor-mediated 
aberrant VSMC proliferation and hypertrophy, linking HDACs to vascular pathophysiology 
(110,111,112).  
 
4.2HDAC system and classes 
 As mentioned above, HDACs are a group of enzymes that lead to deacetylation of lysine 
residues on histones. They have also been shown to deacetylate non-histone proteins as well 
(113). At least 18 different mammalian HDAC genes have been identified, which can be 
categorized into four classes based on structure, function and the associated yeast orthologue. 
The four classes are class I HDACs (HDAC1, 2, 3 and 8), class II (HDAC4, 5, 6, 7, 9, 10), class 
III HDACs (sirtuins), and class IV HDAC (HDAC11). Classes I, II and IV HDACs have been 
termed classical HDACs as they require zinc as a cofactor, while class III HDACs require NAD+ 
as a cofactor (114). Class II HDACs are further subdivided into class IIa (HDAC 4, 5, 7 and 9) 
and class IIb (HDAC 6 and 10) based on their primary structure. In contrast to class IIb HDACs,  
class IIa HDACs contain a large N-terminal regulatory domain involved in protein-protein 
interactions, in addition to a C-terminal catalytic domain (115).  Class IIa HDACs seem to have 
critical roles in many disease processes, including CVDs. For example, HDAC4 and HDAC5 
have been shown to be critical in promoting VSMC proliferation and migration in response to 
growth factors and vasoactive peptides (110, 111, 116) and HDAC7 has been linked to PDGF-
BB-induced endothelial cell migration (117).                              
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4.3HDAC localization 
HDAC localization, which can either be nuclear or cytoplasmic, greatly affects HDAC 
activity. HDACs that are able to shuttle in and out of the nucleus have been shown to regulate 
various cytoplasmic processes and function as signal transducers (118). Localization varies 
depending on the class. Class I HDACs are primarily located in the nucleus with the exception of 
HDAC3, which can also translocate into the cytoplasm. In contrast, class II HDACs are able to 
shuttle in and out of the nucleus. Some Class III and IV HDACs can also shuttle between the 
nucleus and cytoplasm, while others are confined to either the nucleus or the cytoplasm (114). 
Table 1 summarizes the HDAC classes, the members of each class and their localization.  
 
 
HDAC class Members Localization 
Class I HDAC 1 Nucleus 
 HDAC 2 Nucleus 
 HDAC 3 Nucleus/Cytoplasm 
 HDAC 8 Nucleus 
Class II HDAC 4 Nucleus/Cytoplasm 
 HDAC 5 Nucleus/Cytoplasm 
 HDAC 6 Nucleus/Cytoplasm 
 HDAC 7 Nucleus/Cytoplasm 
 HDAC 9 Nucleus/Cytoplasm 
 HDAC 10 Nucleus/Cytoplasm 
Class III SIRT1 Nuclear 
 SIRT2 Cytoplasm 
 SIRT3 Nucleus/Cytoplasm 
 SIRT4 Cytoplasm 
 SIRT5 Cytoplasm 
 SIRT6 Nuclear 
 SIRT7 Nuclear 
Class IV HDAC 11 Nucleus/Cytoplasm 
 
Table 1: HDAC classes and localization. This figure illustrates the four HDAC classes, the 
members of each class and their localization (113, 114).  
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4.4 HDAC structure 
Despite the fact that it has been over 50 years since Allfrey and coworkers first proposed 
the idea that the acetylation status of the histone proteins that make up chromatin is correlated 
with the transcriptional status of a given gene (119), information regarding HDAC structure has 
only become available more recently. Due to their comparable enzymatic activities, it would be 
expected that the proteins within the HDAC superfamily share some structural features. A study 
of the available structural information reveals that this is indeed true.  In humans, HDACs are 
divided into separate classes based on sequence similarities. The Class I proteins (HDAC1, 
HDAC2, HDAC3, HDAC8) have a sequence similarity that extends over 300 residues with the 
yeast Rpd3 protein. Within this 300 residue sequence, there is an especially marked homology 
within an internal ∼70 residue stretch (120). To be specific, 80% similarity was found between 
yeast Rpd3 and human HDAC1 within the 300 residue region of conservation and 99% 
homology in the 70 residue stretch (120).  The Class II HDAC proteins (HDAC4, HDAC5, 
HDAC6, HDAC7, HDAC9 and HDAC10) have a comparable sequence with the yeast Hda1 
protein. Additionally, mammalian Class I and II HDACs were also found to be related to 
Saccharomyces cerevisiae Hos1, Hos2 and Hos3 proteins, which have 35-49% identity to Rpd3 
and 21-28% identity to Hda1 (121). The Class III proteins (SIRT1, SIRT2, SIRT3, SIRT4, 
SIRT5, SIRT6, and SIRT7) and the yeast Sir2 protein have a comparable sequence (113). The 
Class IV protein (HDAC11) has a comparable sequence to both Class I and II proteins (113). 
Figure 4 shows domain organization of human HDACs (113).  
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Figure 4: This figure illustrates domain organization of human HDACs. The total number 
of amino acid residues in each HDAC is shown. Also, only the longest isoform is shown for 
simplicity, despite the fact that HDACs have several isoforms. Enzymatic domains (or 
putative enzymatic domains) are shown in colors (113).  
 
 
Class I and II HDACs have some structural similarities to Class III HDACs in that they 
all contain a central parallel β sheet network that is flanked on opposite sides by helix-rich 
segments (120). Moreover, sequence conservation studies suggest that, in all three HDAC 
classes, substrate binding and catalysis is mediated by the domain proximal to the C-terminal tip 
of the β sheet. This domain is rich in loop segments that appear to be critical for function as they 
form protein cavities that are implicated in acetyl-lysine binding (122). Despite these marked  
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similarities, there are also striking structural differences between the Class I/II and Class III 
HDACs. Most notably is the small globular region in Class III HDACs, which is absent in Class 
I/II HDACs. This region is important for class III HDAC deacetylase activity and, due to its 
sequence and structural divergence, it plays a modulatory role in substrate specificity within the 
class III HDAC family (120). The absence of a corresponding domain in Class I/II HDACs 
suggests that other proteins may substitute for this domain in vivo. This is consistent with the 
observation that Class I/II HDACs associate with other proteins in vivo for catalytic activity 
(120).  
 
  4.5. HDAC expression and regulation 
       4.5.1 Class I HDACs 
In terms of HDAC expression and regulation, Class I HDACs are ubiquitously expressed 
nuclear enzymes; however, it has been shown that HDAC8 is generally poorly expressed (118). 
Not a great deal is known about HDAC3 and HDAC8 regulation, but the other Class I HDACs 
(HDAC1 and HDAC2) form homo- and heterodimers between each other (123,124), which is a 
requirement for HDAC activity. Dissociation of the dimer will impede HDAC activity, which is 
something viruses take advantage of to hinder HDAC activity. For example, it has been shown 
that, by binding to the N-terminal region of HDAC1 and likely dissociating the dimer, the 
adenoviral protein GAM1 impedes HDAC1 activity (125). The level of HDAC1 and HDAC2 
heterodimers is likely cell type-specific, because it was demonstrated that 80% to 90% of 
HDAC1 and HDAC2 proteins formed dimers in the nucleus of human breast cancer MCF-7 cells 
(126), whereas, in mouse embryonic fibroblasts, 40% to 60% of HDAC1 and HDAC2 proteins 
were shown to be free from each other (127). Additionally, Class I HDACs depend on the 
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presence of a catalytic Zn2+ ion for their activity and have been shown to be sensitive to 
inhibition by a family of small molecule compounds that have homology to trichostatin (TSA) 
such as suberoylanilide hydroxamic acid (SAHA) and trapoxin (TPX) (128). 
         
       4.5.2 Class II HDACs 
Like Class I HDACs, Class II HDACs also depend on the presence of a catalytic Zn2+ ion 
for their activity. Class II HDACs, as previously mentioned, shuttle between the nucleus and 
cytoplasm and have tissue-specific expression and functions (128).  
 
4.5.2a Class IIa HDACs 
Class IIa HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) are important signal 
transducers. In the regulatory N-terminal domain of these HDACs, there are several conserved 
serine residues that are subject to reversible phosphorylation. An array of kinases and 
phosphatases acting downstream of diverse biological pathways have been demonstrated to act 
on these HDACs, regulating their nucleocytoplasmic trafficking. On HDAC4, this 
phosphorylation occurs on serine 246 (S246), S467 and S632 by several isoforms of the 
calcium/calmodulin-dependent kinase (CaMK) family (129, 130), by Aurora B on S265 (131), 
by Mirk/dtrk1B on S266 (132), and by glycogen synthase kinase 3β (GSK3β) on S298 and S302 
(133). The critical residues on HDAC5 are S259 and S498 and have been shown to be 
phosphorylated by CaMK-1, -II and –IV, protein kinase D (PKD) and AMPK (134,135,136). 
Protein kinase C (PKC), an upstream regulator of PKD, has also been shown to phosphorylate 
S259 directly (137). For HDAC7, the critical residues are S181, S155, S358 and S486 (138). The 
latter three sites can be modified by CaMK1, whereas PKD can phosphorylate all four residues.             
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Less is known about HDAC9, but it has been suggested that HDAC9 residues S239, S240 and 
S253 are phosphorylated by Aurora B, Mirk/dtrk1B and PRK1, respectively (138). Class IIa 
HDAC phosphorylation leads to the binding of 14-3-3 proteins, the nuclear export of these 
HDACs and the de-repression of their target genes (139).  
 
4.5.2b Class IIb HDACs 
Class IIb HDACs (HDAC6 and HDAC10) have duplicated catalytic domains, however the 
duplication is only partial in the case of HDAC10 (140). HDAC6 and HDAC10 shuttle between  
nucleus and cytoplasm, but their location is primarily cytoplasmic (141). Not much is known 
regarding class IIb HDAC regulation and expression. 
 
4.5.3 Class III HDACs 
Class III HDACs, also known as sirtuins (SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, 
SIRT7), are NAD+ dependent and the availability of NAD+ in cells is a limiting step in the 
activation of sirtuin catalytic activity (142). The basal intracellular NAD+ levels are maintained 
relatively constant (143) through NAD+ biosynthetic and salvaging pathways (144). By 
consuming NAD+ in order to exert their effects, sirtuins regulate the fluctuation of the 
NAD+/NADH ratio. Additionally, sirtuin gene expression has been shown to be under the control 
of numerous transcription factors involved in cell cycle regulation and apoptosis. Among them 
the transcription factor E2F1, which induces cell cycle progression from G1 to S phase, directly 
binds to the Sirt1 promoter upregulating its gene expression in cells treated with the  
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topoisomerase II inhibitor etoposide (145). Furthermore, the tumour suppressor p53, which is 
one of the most extensively mutated proteins in cancers, has also been shown to affect Sirt1 gene 
expression. Two functional p53-binding sites have been identified in the regulatory region of the 
Sirt1 promoter and studies have indicated that in nutrient-deprived mammalian cells p53 
stimulates Sirt1 gene expression (146). On the contrary, in normal nutrient conditions, p53 
mediates repression of Sirt1 gene expression (147). Sirt1 levels are regulated by E2F1 and p53 at 
the transcriptional level as well as the translational level.   
 
Sirtuin activity is also regulated by posttranslational modifications. In vitro evidence has 
demonstrated that cyclin B/Cdk1-mediated dephosphorylation at specific sites decreases Sirt1 
and Sirt2 deacetylase activity (148). Additionally, Sirt1 has also been shown to be 
phosphorylated by the c-Jun N-terminal kinase 2 (JNK2) (149) and casein kinase 2 (CK2) (150). 
JNK2-mediated phosphorylation of Sirt1 is associated with the regulation of its protein stability 
(149). Furthermore, several conserved phosphorylation sites have been found within Sirt1 that 
are possible targets for a variety of kinases such as ATM, casein kinase 1 (CK1), DNA-
dependent protein kinase (DNA-PK), extracellular-signal-regulated kinase (ERK1), GSK-3, IκB 
kinase (IKK), and MAPK (148). It is not known, however, if these kinases phosphorylate only 
Sirt1 or other members of the sirtuin class as well. In addition to phosphorylation, other 
posttranslational modifications that may regulate sirtuin deacetylase activity include acetylation 
and sumoylation.  
 
       4.5.4 Class IV HDACs 
The Class IV HDAC (HDAC11) has sequence similarity to Class I and II HDACs. Aside 
from this, little is known of its function and regulation (113).                                                      30 
 
 
 
4.6.   HDAC activation and signaling in vascular pathophysiology 
 
       4.6A Vasoactive peptide-induced HDAC activation and signaling  
Angiotensin II (AngII), a potent vasoconstrictor, has been shown to activate several signaling 
pathways linked to cellular hypertrophy, growth, migration and proliferation in various cell types 
including VSMCs. One of its targets is CaMKII, which transduces downstream signaling 
responses of AngII upon activation (151). A potential transcriptional target for CaMKII is 
myocyte enhancing factor 2 (MEF2). MEF2, a DNA binding transcription factor which likely 
promotes the synthetic phenotype of VSMCs, can either act as an activator or a repressor of 
transcription depending on its interaction with co-activators or co-repressors, respectively (152). 
HDAC4 and HDAC5 have been shown to directly interact with MEF2 in the nucleus to promote 
its repressive activity. Consequently, HDAC4 and HDAC5 phosphorylation and nuclear export 
increases MEF2 transcriptional activity and leads to VSMC hypertrophy (152). As recently 
reported, CaMKII is capable of mediating AngII-dependent increases in HDAC4 (S467) (153) 
and HDAC5 (S498) (154) phosphorylation and subsequent nuclear export. This derepresses 
MEF2, increasing MEF2 DNA binding activity and transcription. Additionally, it was 
demonstrated that HDAC5 phosphorylation is mediated by HDAC4 in VSMCs, suggesting a 
potential regulatory mechanism involving protein-protein interaction (154). Figure 5 illustrates 
CaMKII-dependent nuclear export of HDAC4 and HDAC5.  
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Figure 5: This model depicts CaMKII-dependent nuclear export of HDAC4 and HDAC5. 
Following AngII stimulation, CaMKII specifically phosphorylates HDAC4 at S467 and 
HDAC5 at S498 (sites not shown in model), resulting in 14-3-3 protein-mediated nuclear 
export. Following HDAC4 and HDAC5 nuclear export, MEF2 is derepressed and MEF2-
dependent gene transcription is activated (154).  
 
Based on evidence from different cell types, class IIa HDACs have been shown to have many 
transcription factor targets in addition to MEF2, including serum response factor (SRF), which 
has been linked to CaMKII and HDAC4 in cardiomyocytes (155). Davis et al. showed that 
HDAC4 interacts with SRF in cardiomyocytes and this interaction is enhanced by AngII 
stimulation (155). Thus, MEF2 is unlikely to be the only transcription factor targeted by CaMKII 
and class IIa HDACs in VSMCs. 
 
As suggested above, there are many pathways and factors involved in propagating 
hypertrophic and proliferative signals in VSMCs. As evidenced by Pang et al., G-protein coupled 
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 receptor (GPCR)-kinase 2 interacting protein-1 (GIT1) has been shown to be involved in 
mediating HDAC5 phosphorylation by AngII (156). AngII stimulation leads to GIT1 
phosphorylation, causing PLCγ activation which is required for elevation of intracellular Ca2+ 
and activation of CaMKII. Once CaMKII is activated, it phosphorylates HDAC4 and HDAC5 
leading to nuclear export (152). 
 
In contrast to CaMKII-dependent HDAC4 and HDAC5 phosphorylation, other studies have 
shown that AngII is able to induce HDAC5 phosphorylation and nuclear export in VSMCs in a 
calcium independent manner (157). As evidenced by Xu et al., AngII has been shown to induce 
HDAC5 phosphorylation and export via the protein kinase C (PKC)-protein kinase D1 (PKD1) 
pathway. PKD1 has been shown to phosphorylate HDAC5 at Serine 259/498 (157). PKC has 
also been shown to phosphorylate Serine 259 directly in the tissue of failing hearts (158). Once 
phosphorylated, these residues serve as docking sites for 14-3-3 chaperone proteins. This results  
in an increase in MEF2 transcriptional activity, which derepresses VSMC growth genes and 
consequently leads to VSMC hypertrophy (116).  
 
      4.6B Growth factor-induced HDAC phosphorylation and activation 
In addition to vasoactive peptides, like AngII, growth factors are also involved in HDAC-
related vascular pathophysiology. In VSMCs, HDAC4 and HDAC5 have been shown to be 
phosphorylated by CaMKII in response to Platelet-Derived Growth Factor-BB (PDGF-BB) 
(159).  
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PDGF-BB is a key mediator of VSMC phenotype switching from the contractile state to 
the synthetic state (160). As previously described, this switch is associated with suppressed 
expression of VSMC marker genes, such as smooth muscle ⍺-actin and smooth muscle myosin 
heavy chain, as well as increased proliferation and migration rates of cultured VSMCs. It has 
been shown by Yoshida et al. that PDGF-BB represses the expression of VSMC marker genes 
through the recruitment of HDAC4 and HDAC5 to the promoters of these genes (161). HDAC-
induced hypoacetylation inhibits the accessibility of transcription factors, notably SRF, to 
interact with the promoters of these genes, reducing transcription (162). Additionally, HDAC5 
has been shown to directly interact and inhibit myocardin, SRF’s coactivator, which also 
contributes to decreased transcription of marker genes (163). In terms of proliferation and 
migration, PDGF-BB- induced HDAC4 phosphorylation is involved in mediating proliferation  
and migration of VSMCs (164). HDAC4 knockdown was shown to inhibit PDGF-induced 
expression of cyclin D1, a cell cycle regulatory protein required for the progression of the G1 
phase, which has an inhibitory effect on proliferative signals (165). Furthermore, Usui et al. also 
illustrated the involvement of HDAC4 in PDGF-BB-induced VSMC migration and cytoskeletal 
reorganization (164). Both migration and cytoskeletal reorganization were shown to be 
significantly inhibited by HDAC4 siRNA as well as MC1568, a Class IIa HDAC inhibitor (164). 
 
In addition to VSMC phenotype switching, it is likely that PDGF-BB also increases ROS 
production by upregulating NOX activity in an HDAC4-dependent manner, as evidenced by  
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HDAC4 siRNA studies (166). Once HDAC4 is phosphorylated by PDGF-BB in a CaMKII-
dependent manner, it is believed that HDAC4 might upregulate NOX activity via p47 phox or 
Rac-1 activation (167). Upregulation of NOX activity will cause increased ROS, which can 
stimulate VSMC proliferation and migration via the activation of p38MAPK/HSP27 signals 
(167). 
 
In terms of the specific signaling cascades activated during PDGF-BB-mediated vascular 
pathophysiology, CaMKs and PKC/PKD are known to be activated by PDGF-BB leading to 
VSMC migration and proliferation (168, 169). HDAC4 has been shown to be a substrate for 
activated CaMKII (170). It has been suggested that PDGF-BB stimulation causes CaMKIIδ to 
sequester HDAC4 to the cytoplasm, thereby stimulating MEF2 activity in VSMCs (152).   
 
            4.6C Prostanoids and B-adrenergic agonists-induced HDAC activation and signaling 
In contrast to vasoactive peptides and growth factors, which contribute to vascular 
disease, prostanoids, such as prostacyclin, and β-adrenergic agonists decrease cardiovascular risk 
(171). Prostacyclin and β-adrenergic agonists activate protein kinase A (PKA), which has been 
shown to minimize the incidence of cardiovascular disease by opposing VSMC proliferation 
(171). Although the mechanisms underlying this process have not yet been fully elucidated, PKA 
has been shown to promote HDAC4-induced repression of MEF2-dependent gene expression 
(172). 
 
4.7. Involvement of HDACs in cardiovascular pathophysiology 
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The majority of CVDs, such as hypertension and atherosclerosis, are the result of 
vascular remodeling mediated in part by VSMC proliferation and migration. HDACs, notably 
Class IIa HDACs, have been associated with this process (173). 
 
4.7A Hypertension 
HDAC4 is of particular importance in disease as it has been linked to the promotion of 
hypertension. Proliferation and migration of VSMCs leads to medial thickening and structural 
remodeling, also known as neointimal hyperplasia. Neointimal hyperplasia is one of the major 
processes underlying hypertension development. Through the use of MC1568, a Class IIa HDAC  
inhibitor, it was suggested that HDAC4 is at least partly responsible for neointimal hyperplasia 
and, consequently, has a role in hypertension development (174).  
 
Vascular inflammation is also known to be important in the pathogenesis of hypertension. 
In particular, inflammation induced by ROS has been suggested to have a critical role in the 
development of hypertension via promoting proliferation and migration of VSMCs (175). Class 
IIa HDACs have been linked to this process and HDAC4 is of particular importance. It has been 
demonstrated that HDAC4 promotes ROS-dependent vascular inflammation and likely mediates 
the further development of hypertension in spontaneously hypertensive (SHR) rats (176). In 
these rats, HDAC4 has been shown to mediate ROS-dependent VSMC proliferation and 
migration through the activation of p38 MAPK/ HSP27 (176). 
 
4.7B Atherosclerosis 
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VSMCs undergo a switch from the contractile to the synthetic phenotype in response to 
various stimuli, such as shear stress, lipids, ROS and cytokines, giving rise to a state favoring 
migration and proliferation (177). VSMCs recruited from the media to the intima, as well as  
those proliferating within the intima, contribute to progression of atherosclerosis. They secrete 
large quantities of extracellular-matrix components, such as collagen, resulting in atherogenic 
lipoprotein retention and aggregation (178). Additionally, migrating and proliferating smooth 
muscle cells beneath the endothelium form a fibrous cap, cutting the blood supply from the 
plaque (179). Thus, it is evident that smooth muscle cell proliferation and migration are key 
events in the development of atherosclerosis. HDACs are implicated in this process as studies 
have shown that they play a critical role in the VSMC phenotype switch needed for the 
progression of atherosclerosis. Class IIa HDACs have been shown to promote the phenotype 
switch of smooth muscle cells though Ca2+ signals (180). As previously mentioned, in addition 
to the phenotypic switch, VSMC migration and proliferation are also integral to the development 
of atherosclerotic vascular disease. Studies have indicated that HDAC4 and HDAC5, following 
phosphorylation by PKD1 and CaMKII, promote PDGF-BB-induced VSMC proliferation and 
migration via activating the p38 MAPK/HSP27 pathways, ultimately contributing to neointimal 
hyperplasia, vascular remodeling and the atherosclerotic plaque formation (181,182).  
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5. Goal of this study 
IGF-1, a potent mitogenic and vasoactive factor, has been shown to play a role in the 
development of CVDs. This occurs through the hyperactivation of mitogenic and growth 
promoting signaling pathways and the subsequent alteration in gene expression induced by IGF-
1. HDACs, by their ability to modify the acetylation status of the lysine residues in histone and 
non-histone proteins, regulate the transcription of genes involved in cell growth, proliferation 
and migration. Recent studies have demonstrated that a heightened activation of HDACs, notably 
HDAC5, is associated with vascular disorders such as atherosclerosis. However, a role of IGF-1 
in HDAC activation by phosphorylation remains poorly characterized. More importantly, despite 
the fact that IGF-1 receptor activation leads to a potent stimulation of the ERK1/2 and PKB 
pathways, the involvement of these pathways in HDAC phosphorylation and nuclear export has 
not been explored in VSMCs. Therefore, in the present studies, we examined the effect of IGF-1 
on the phosphorylation and nuclear export of HDAC5 in VSMCs and identified the signaling 
pathways involved in this process. 
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Abstract 
 
Insulin-like growth factor 1 (IGF-1), a potent mitogenic and vasoactive factor, has 
been shown to play a role in the development of cardiovascular diseases. This occurs 
through the generation of reactive oxygen species (ROS) as well as through the 
hyperactivation of mitogenic and growth promoting signaling pathways and the 
subsequent alteration in gene expression. Histone deacetylases (HDACs), by their ability 
to modify the acetylation status of the lysine residues in histone and non-histone proteins, 
regulate gene transcription. Recent studies have demonstrated that a heightened 
activation of HDACs, notably HDAC5, is associated with vascular disorders such as 
atherosclerosis. However, a role of IGF-1 in HDAC phosphorylation and activation has 
not been investigated. Therefore, in the present studies, we examined the effect of IGF-1 
on the phosphorylation of HDAC5 in vascular smooth muscle cells (VSMCs) and 
identified the signaling pathways involved in this process. Treatment of A10 VSMCs 
with IGF-1 enhanced the phosphorylation of HDAC5 at serine 498 in a time and dose-
dependent fashion. Pretreatment of cells with AG1024, a selective pharmacological 
inhibitor of IGF-1R, significantly inhibited IGF-1-induced HDAC5 phosphorylation in 
A10 VSMCs whereas AG1478, a selective inhibitor of epidermal growth factor receptor 
(EGFR), did not have an inhibitory effect on the levels of phospho-HDAC5. 
Pharmacological blockade of the MAPK pathway with PD98059, UO126, SP600125 and 
SB203580 had no effect on HDAC5 phosphorylation, whereas inhibitors of the PI3K/ 
PKB pathways, wortmannin and SC-66 respectively, almost completely attenuated IGF-
1-induced HDAC5 phosphorylation. These findings were confirmed by 
immunofluorescence localization of phospho-HDAC5 and by siRNA- induced silencing 
of PKB. In addition, pretreatment of A10 VSMCs with Diphenyleneiodonium (DPI) and 
apocynin, two NAD(P)H oxidase inhibitors, as well as the antioxidant N-Acetyl-Cysteine 
(NAC), resulted in an attenuation of IGF-1-induced phosphorylation of HDAC5 as well 
as PKB. Furthermore, siRNA-induced silencing of Nox4, the main NADPH oxidase 
expressed in VSMC, inhibited IGF-1 induced HDAC5 phosphorylation. Moreover, IGF-
1-induced phosphorylation of HDAC5 resulted in its nuclear export, which was reversed 
by blockade of PKB by SC-66 or NAD(P)H oxidase inhibition by DPI. In summary, 
these data demonstrate that IGF-1 induces the phosphorylation and nuclear export of 
HDAC5 in a Nox4-derived ROS- and PKB-dependent fashion in VSMCs. 
 
Keywords: IGF-1, HDAC5, PKB, PI3-K, MAPK, ROS, VSMC 
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Introduction 
 
Cardiovascular diseases (CVDs) are associated with the increasingly high morbidity and 
mortality rates worldwide (1). The main feature of CVD is an increased vascular resistance due 
to blood vessel remodeling. Blood vessels are lined by vascular smooth muscle cells (VSMCs), 
which are highly specialized cells that regulate vascular tone and blood pressure (2). Abnormal 
migration, growth and proliferation of VSMCs are believed to be key events that contribute to 
structural remodeling of blood vessels and have been attributed to the pathogenesis of vascular 
diseases such as intimal hyperplasia, hypertension, atherosclerosis and restenosis (3-7). A 
potential role of vasoactive peptides and growth factors in inducing proliferation, hypertrophy, 
migration and differentiation of VSMCs has been demonstrated (8-11). We have shown earlier 
that transactivation of insulin-like growth factor 1 (IGF-1) receptor is critical to induce the 
mitogenic and hypertrophic responses of two key vasoactive peptides, angiotensin II (AngII) and 
endothelin-1 (ET-1) (12). Recent studies have demonstrated that a heightened activation of 
histone deacetylases (HDACs), notably HDAC4 and HDAC5, is associated with increased 
proliferation, migration and hypertrophy of VSMCs (13-16). However, a role of IGF-1 in HDAC 
activation has not been investigated. More importantly, despite the fact that IGF-1 receptor 
activation leads to a potent stimulation of mitogen activated protein kinases (MAPK) and 
phosphatidyl-inositol-3-kinase (PI3K)/protein kinase B (PKB) pathways (17, 18), the 
involvement of these pathways in HDAC phosphorylation and nuclear export remains 
unexplored in VSMCs. Therefore, in the present studies, we examined the effect of IGF-1 on the 
phosphorylation and nuclear export of HDAC5 in VSMCs and identified the signaling pathways 
involved in this process. 
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Materials and Methods 
Antibodies and reagents: 
Cell culture reagents were obtained from Invitrogen Corp. (Grand Island, NY, USA) and 
IGF-1 was purchased from Peprotech Inc. (Rocky Hill, NJ, USA).  AG1024 (IGF-1R inhibitor), 
AG1478 (EGFR inhibitor), PD98059 (MEK1 inhibitor), SP600125 (JNK inhibitor), SB203580 
(p38 inhibitor), UO126 (MEK1 and MEK2 inhibitor), wortmannin (PI3-K inhibitor), SC-66 
(AKT inhibitor) and DPI (NAD(P)H oxidase inhibitor) were purchased from Calbiochem (San 
Diego, CA, USA). NAC (ROS scavenger) was obtained from Sigma-Aldrich (Oakville, ON, 
Canada). Apocynin (NAD(P)H oxidase inhibitor) was purchased from Cayman Chemical (Ann 
Arbor, MI, USA). Total (#SC154) and phosphorylated ERK1/2 (#SC16982-R) antibodies as well 
as total HDAC5 (#SC11419) and Nox4 (#SC21860) were purchased from Santa Cruz 
Biotechnology (Dallas, TX, USA). β-tubulin (#2146S), total PKB (#9272S), phosphorylated 
PKB (#3787S), phosphorylated p38 MAPK (#4511S), phosphorylated JNK (#9251S), Lamin B1 
(#12586) and anti-rabbit (#7074S) antibodies were obtained from Cell Signaling (Beverly, MA, 
USA). Phosphorylated HDAC5 (Serine 498) (#AB47283) was purchased from Abcam Inc 
(Toronto, ON, Canada). Alexa Fluor 488 goat anti-rabbit IgG (#A-11034) was obtained from 
Life Technologies, Molecular Probes (Grand Island, NY, USA). The enhanced 
chemiluminescence (ECL) detection system kit was from Perkin Elmer (Montreal, QC, Canada). 
Lipofectamine RNAi max (#13778-075) was provided by Life Technologies (Burlington, ON, 
Canada); SCR (#SR30004), PKB (#SR500756), and Nox4 (#SR506919) siRNA duplexes were 
obtained from Origene (Rockville, MD, USA).  
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Cell culture: 
A10 VSMCs derived from the thoracic aorta of embryonic rats (CRL-1476 from ATCC 
(Manassas, VA, USA)) were maintained in culture with Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin, in a 
humidified atmosphere of 5% CO2 exchange at 37°C. They were sub-cultured twice a week by 
harvesting them with trypsin/ ethylenediaminetetraacetic acid (EDTA). The cells were grown to 
80-90% confluence in 60-mm culture plates and made quiescent by incubating in FBS-free 
DMEM 5h prior to experimental treatment.  
 
Cell lysis and immunoblotting: 
 
Confluent serum-starved A10 VSMCs were incubated in the absence or presence of 
various reagents for 30 minutes, followed by stimulation with 50ng/ml IGF-1 (based on previous 
experiments performed in our lab, this was found to be the optimal concentration) for 5 min. The 
cells were washed three times with ice-cold PBS and lysed in 100 µL radio-immunoprecipitation 
(RIPA) buffer. Equal amounts of proteins measured by Bradford assay were subjected to 10% 
SDS-polyacrylamide gel electrophoresis, transferred to Immobilion-P polyvinylidinedifluoride 
membranes (Millipore, USA) and incubated overnight with respective primary antibodies: 
pHDAC5 (1:1000), total HDAC5 (1:1000) phospho-ERK1/2 (1:2000), total ERK1/2 (1:4000), 
total PKB (1:2000)  phospho-PKB (1:2000), phospho-JNK (1:2000), total JNK (1:2000) 
phospho-p38 (1:2000), total p38 (1:2000) lamin B1 (1:2000), Nox4 (1:500) and β-tubulin 
(1:5000).  The antigen-antibody complex was detected by horseradish peroxidase-conjugated 
secondary antibody (1:4000), and protein bands were visualized by ECL. The intensity of the 
bands was quantified by densitometric analysis using Quantity One Bio-Rad Corp. imaging and 
Graphpad Prism 5 (San Diego, CA, USA) software programs.                                                     45 
 
 
 
Transfection with siRNA: 
Silencing of PKB or Nox4 was achieved by transfecting the VSMCs with specific small 
interfering RNAs as described earlier (19). VSMCs were transfected with siRNA duplexes 
against PKB or Nox4 or with non-specific duplexes (scrambled) according to the manufacturer’s 
protocol. A mixture of the desired siRNA (PKB or Nox4) with lipofectamine or a mixture of 
scrambled siRNA with lipofectamine was added to the cells for a final concentration of 10 nM 
siRNA. The cells were incubated for 48h at 37oC prior to treatment with IGF-1 or other agents. 
 
Immunofluorescence:  
 
Serum-starved A10 cells grown and treated on glass coverslips were washed with iced 
cold PBS and fixed with paraformaldehyde 4% for 30 min at 4°C. Permeabilization was 
achieved by 10 minutes incubation with 0.1% Triton X-100, 0.1% serum citrate pH 4.0 at room 
temperature (RT). Cells were then blocked with goat serum diluted in PBS (15 µL/mL PBS) for 
1 hour and incubated overnight at 4°C with phospho-HDAC5 antibody diluted in the same 
blocking solution (1:100). Coverslips were further incubated for 2 hours at RT with Alexa Fluor 
488 goat anti-rabbit IgG (1:150) Nuclei were then labelled by staining the coverslips with DAPI 
(2 µL/1.5 mL H2O) before mounting them with a buffer made of 30% Glycerol in PBS. The 
images were taken using X-Cite Serie 120, TE2000-S fluorescence microscope (17). 
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Nuclear extraction protocol: 
 To separate the nuclear and cytosolic protein fractions, cells incubated in the absence or 
presence of pharmacological agents were lysed and nuclear and cytosolic protein were isolated 
for subsequent immunoblotting. Briefly, cells were washed three times with ice-cold PBS and 
collected in a 100µl buffer solution containing 10mM Hepes, 10mM KCl, 0.1mM EDTA, 
0.1mM EGTA, 1mM PMSF, 1mM protease cocktail inhibitor and 1mM NaOV. Lysates were put 
on ice for 15 minutes before the addition of 10% NP40 detergent.  Lysates were then vortexed 
for 10 seconds at highest setting before centrifugation at 18,327xg for 4 minutes at 4oC. The 
supernatant (corresponding to the cytoplasmic fraction) was saved and transferred in a clean 
tube. The pellet was resuspended in 60µl, by pipeting up and down several times, in buffer 
containing 10mM Hepes, 400mM NaCl, 0.1mM EDTA, 0.1mM EGTA, 1mM PMSF, 1mM 
protease cocktail inhibitor and 1mM NaOV. Lysates were sonicated by performing 6 cycles at 10 
seconds per cycle with 30 second intervals and then centrifuged at 18,327xg for 5 minutes at 
4oC. Pellet was discarded and the supernatant, corresponding to the nuclear fraction, was 
collected. Protein concentrations were measured using Bradford assay (17). 
 
Statistics: 
Statistical analysis was performed by one-way, standard analysis of variance (ANOVA). 
Significance of the differences between samples was assessed by a Tukey post hoc test. All data 
are reported as means ± SE of at least three different experiments. The differences between 
means were considered significant at p< 0.05. 
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Results 
IGF-1 induces HDAC5 phosphorylation in a dose and time-dependent fashion through the 
IGF-1R in A10 VSMCs 
 
Despite the fact that IGF-1 is a potent mitogen and is implicated in vascular dysfunction, 
its ability to induce phosphorylation of HDAC5 in VSMCs has not been explored. Therefore, we 
examined the effect of IGF-1 on HDAC5 phosphorylation in A10 aortic VSMCs. As depicted in 
Fig. 1A, treatment of VSMCs with IGF-1 increased HDAC5 phosphorylation at Ser498 in a 
dose-dependent manner, with 10ng/mL being the minimum required dose. Further increasing the 
IGF-1 concentration maintained the same level of HDAC5 phosphorylation. In addition, 
immunoblotting and immunofluorescence studies revealed that IGF-1-induced HDAC5 
phosphorylation was very rapid, with a peak at 5 min and then a quick decline thereafter (Figs 
1B and 1C). In order to confirm the involvement of IGF-1R in IGF-1-induced HDAC5 
activation, we used AG1024, a highly specific inhibitor of IGF-1R tyrosine kinase activity. As 
depicted in Fig. 2, the use of AG1024 potently inhibited IGF-1-induced HDAC5 phosphorylation 
compared to cells treated with IGF-1 alone. Additionally, the use of AG1478, an inhibitor of 
EGFR tyrosine kinase activity, did not inhibit IGF-1-induced HDAC5 phosphorylation, further 
demonstrating the specific involvement of IGF-1R in this process (Fig. 2).  
 
IGF-1-induced HDAC5 phosphorylation is not MAPK pathway dependent 
 
IGF-1 has been show to mediate its pathophysiological effects through the activation of 
hypertrophic and growth promoting signaling pathways, including the mitogen-activated protein  
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kinase (MAPK) pathway (17, 18). Therefore, we next investigated whether the MAPK pathway  
was involved in mediating IGF-1-induced HDAC5 phosphorylation. To investigate this and to 
identify which MAPKs are specifically involved in IGF-1-induced HDAC5 activation, a variety 
of pharmacological inhibitors were used. These included PD98059 and UO126, MEK1/2 
inhibitors, as well as SP600125, a JNK inhibitor, and SB203580, a p38 MAPK inhibitor. As 
shown in Fig. 3, HDAC5 phosphorylation was strongly enhanced by IGF-1 and none of the 
MAPK inhibitors used attenuated this effect. These data indicated that the MAPK pathways are 
not involved in IGF-1-induced HDAC5 phosphorylation in A10 VSMCs. 
 
Activation of the PI3-K/PKB pathway is required for IGF-1-induced HDAC5 
phosphorylation in A10 VSMCs 
 
 Activation of the PI3-K/PKB pathway is critical to induce the cellular responses of IGF-1 
(18). Therefore, to investigate whether the PI3-K/PKB pathway contributes to IGF-1-induced 
HDAC5 phosphorylation, we used wortmannin and SC-66, which are specific pharmacological 
inhibitors of PI3-K and PKB respectively. As shown in Fig. 4A, wortmannin treatment caused a 
significant reduction in HDAC5 phosphorylation in response to IGF-1. Similarly, pre-treatment 
of A10 VSMCs with SC-66 also suppressed IGF-1-induced phosphorylation of HDAC5 (Fig. 
4B). Additionally, as shown in Fig. 4C, immunofluorescence experiments also confirmed that 
SC-66-induced inhibition of PKB reduced HDAC5 phosphorylation stimulated by IGF-1. We 
further probed the involvement of PKB in IGF-1-induced phosphorylation of HDAC5 by siRNA-
mediated silencing of PKB in VSMCs. As shown in Fig 5A, siRNA-induced reduction in PKB 
levels resulted in suppression of HDAC5 phosphorylation in response to IGF-1, as revealed by  
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immunoblotting. Similar to immunoblotting, immunofluorescence microscopy also showed that 
siRNA-induced knockdown of PKB reduced the phosphorylation of HDAC5 (Fig. 5B). These 
data confirm the involvement of the PI3-K/PKB pathway in IGF-1-induced HDAC5 
phosphorylation in VSMCs.  
 
IGF-1 triggers HDAC5 nuclear export in a PKB-dependent fashion in A10 VSMCs 
 HDAC5 phosphorylation has been shown to lead to 14-3-3 chaperone protein binding and 
the subsequent nuclear export of phosphorylated HDAC5, resulting in the derepression of 
HDAC5 target genes (13).  Phosphorylation of HDAC5 by either CaMKII or PKD has been 
shown to induce its nuclear export (13, 16). Therefore, we investigated whether IGF-1-induced 
phosphorylation of HDAC5 was associated with its nuclear export. As shown in Fig. 6, in 
unstimulated cells, HDAC5 is mainly localized in the nuclear fraction; however, treatment of the 
cells with IGF-1 resulted in a decrease in the levels of HDAC5 in the nuclear fraction and a 
concomitant increase in the cytosolic fraction. Moreover, treatment with SC-66, an inhibitor of 
PKB, disrupted the nuclear export of HDAC5, suggesting that IGF-1 stimulates HDAC5 nuclear 
export in a PKB-dependent manner in A10 VSMCs.  
 
ROS generation is required for IGF-1-induced HDAC5 phosphorylation and nuclear 
export in A10 VSMCs 
 
 ROS play a significant role in the pathogenesis of vascular abnormalities (17). IGF-1 has 
been reported to mediate many of its effects through the activation of NAD(P)H oxidase-derived 
ROS generation (20). However, a role of ROS in IGF-1-induced HDAC5 phosphorylation in  
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VSMCs remains unexplored; therefore, with the use of diphenyleneiodonium (DPI) and 
apocynin, two NAD(P)H oxidase inhibitors, as well as N-acetylcysteine (NAC), a ROS 
scavenger, we investigated whether ROS is involved in IGF-1-induced HDAC5 phosphorylation. 
As depicted in Fig. 7, pre-treatment of VSMCs with DPI, NAC and apocynin resulted in a 
marked reduction in HDAC5 and PKB phosphorylation in response to IGF-1. Additionally, since 
Nox4 has been shown to be the main Nox isoform involved in mediating IGF-1’s effects in 
VSMCs (21), we probed the involvement of Nox4 in IGF-1-induced phosphorylation of HDAC5 
by siRNA-mediated silencing of Nox4 in VSMCs. As shown in Fig 8, siRNA-induced reduction 
in Nox4 levels resulted in suppression of HDAC5 and PKB phosphorylation in response to IGF-
1, as revealed by immunoblotting. Furthermore, to investigate whether ROS generation triggers 
IGF-1-induced HDAC5 nuclear export, we treated cells with DPI and found that it disrupted the 
nuclear export of HDAC5, as indicated by high expression of HDAC5 in the nuclear fraction 
(Fig 9). These data suggest the involvement of Nox4-derived ROS generation in IGF-1-induced 
HDAC5 phosphorylation and nuclear export in A10 VSMCs.  
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Discussion 
 
 In this study, we have demonstrated that IGF-1 stimulates the phosphorylation of 
HDAC5 at Serine 498 (Ser498) in A10 VSMCs and have identified the intracellular signaling 
pathways involved in this process. Our data reveal that pharmacological blockers of PI3-K and 
PKB, wortmannin and SC-66 respectively, attenuated IGF-1-induced phosphorylation of 
HDAC5, suggesting that PKB phosphorylates Ser498 on HDAC5 in response to IGF-1 in 
VSMCs. Furthermore, our results demonstrating that siRNA-induced silencing of PKB 
suppressed HDAC5 phosphorylation in response to IGF-1 provided additional support for a role 
of PKB in mediating the phosphorylation of HDAC5 in VSMC stimulated by IGF-1.  
 
IGF-1-induced phosphorylation and activation of MAP kinases is among the first events 
triggered by IGF-1 receptor activation and has been shown to mediate several physiological 
responses of IGF-1 (18, 22). However, with the use of a series of pharmacological blockers of 
ERK1/2, JNK and p38 MAPK, we showed that none of these inhibitors reduced IGF-1-induced 
HDAC5 phosphorylation, suggesting that the MAPK pathway does not play a role in mediating 
IGF-1-induced HDAC5 phosphorylation in VSMCs.  
 
Earlier studies have reported that angiotensin II (AngII), platelet derived growth factor 
(PDGF) and Ca2+ elevating agents induce phosphorylation of HDAC5 at Ser259 and Ser498 in 
VSMCs and in intestinal epithelial cells (13, 15, 16, 21). These studies also identified protein 
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kinase D1(PKD1) (16, 21), which is activated in a protein kinase C (PKC)-dependent manner, 
and calcium/calmodulin-dependent protein kinase II (CaMKII) (13) as the putative protein 
kinases responsible for catalyzing the phosphorylation of these serine residues in HDAC5. 
AngII- and PDGF-induced HDAC5 phosphorylation have been suggested to play a role in 
VSMC proliferation and hypertrophy, and modulate the transcriptional activity of cell cycle 
regulatory proteins (13, 15, 16). However, our studies provide first evidence for a role of PKB in 
mediating IGF-1-induced HDAC5 phosphorylation at Ser498 in VSMCs.  
 
A role of ROS generated by NAD(P)H oxidase 4 (Nox4) in mediating IGF-1 signaling, as 
well as IGF-1’s proliferative and migratory effects has been previously reported (20). We have 
also shown earlier that IGF-1-induced phosphorylation of PKB and enhanced Egr-1 expression 
are mediated by a ROS-dependent pathway (17). Our observation that DPI and apocynin, two 
pharmacological blockers of NAD(P)H oxidase, as well as the ROS scavenger NAC significantly 
reduced both HDAC5 phosphorylation and PKB phosphorylation in response to IGF-1 in 
VSMCs indicated the involvement of ROS in IGF-1-induced HDAC5 phosphorylation in 
VSMCs. Furthermore, our results showing that silencing of Nox4 by siRNA potently reduced 
both HDAC5 and PKB phosphorylation in response to IGF-1 in VSMCs, suggested that Nox4 
activation is critical to enhance ROS generation in response to IGF-1 in VSMCs.  
 
HDAC5 phosphorylation has been shown to result in its exclusion from the nucleus in 
cells treated with AngII, PDGF, and other agents (13, 16). Using nuclear and cytoplasmic 
fractionation techniques, we have also provided evidence that, similar to AngII and PDGF, IGF- 
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1 was also able to induce the nuclear export of HDAC5 in a PKB- and ROS-dependent fashion in 
VSMCs. To the best of our knowledge, the work presented here has revealed a previously 
unidentified role of PI3-K/PKB signaling pathway in inducing the phosphorylation and nuclear 
export of HDAC5 in response to IGF-1 in VSMCs.  
 
In summary, our data demonstrate the involvement of the PI3-K/PKB pathway as well as 
Nox4 as upstream regulators of HDAC5 phosphorylation and nuclear export in response to IGF-
1. Since HDAC phosphorylation has been associated with enhanced migration and proliferation 
of VSMCs by altered expression of genes associated with cell cycle regulation, it may be 
suggested that PKB- and Nox4-generated ROS-induced phosphorylation of HDAC5 in VSMCs 
may constitute a potential mechanism to trigger a signaling program leading to vascular 
remodelling.  
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Figure 1. IGF-1 stimulates HDAC5 phosphorylation in A10 VSMCs in a time and dose-
dependent fashion 
 
Confluent serum-starved quiescent A10 cells were incubated with increasing concentrations of 
IGF-1 for 5 minutes (A) or with 50ng/ml IGF-1 for the indicated time periods (B). Cell lysates 
were probed with pHDAC5 antibody (Ser498), as shown in the top panels of each section (A and 
B). Cell lysates were also probed with pPKB and also analyzed for protein loading using total 
HDAC5. Bar diagrams represent the average quantification of HDAC5 phosphorylation relative 
to total HDAC5. Values are the means ± SE of 3 independent experiments and expressed as a 
ratio where the control values are taken as 1. ***P<0.0005 compared to CTL. (C) shows 
immunofluorescence microscopy of pHDAC5 cellular localization in IGF-1 treated VSMCs. 
Cells growing on coverslips were fixed and stained with anti-phospho-HDAC5 antibody (green 
signal). Nuclei were stained with DAPI (4´,6-diamidino-2-phenylindole) (blue signal). Merged 
pictures show the DAPI-stained image superimposed on the pHDAC5-stained image. Shown are 
representative images from 3 independent experiments. The images were taken using X-Cite 
series 120, TE2000-S fluorescence microscope.  
 
Figure 2. IGF-1 – induced HDAC5 phosphorylation is attenuated by AG1024 (IGF-1R-
PTK inhibitor) and not by AG1478 (EGFR TK inhibitor) in A10 VSMCs 
 
Confluent serum-starved quiescent A10 VSMCs were pre-treated without (-) or with (10µM) 
AG1024 (IGF-1R-PTK inhibitor) or without (-) or with (10µM) AG1478 (EGFR-PTK inhibitor) 
for 30 minutes, followed by stimulation with 50ng/ml IGF-1 for 5 minutes. Cell lysates were 
probed with pHDAC5 antibody, with pPKB and also analyzed for protein loading using a total 
HDAC5 antibody. Bar diagrams represent the average quantification of HDAC5 phosphorylation  
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relative to total HDAC5. Values are the means ± SE of 3 independent experiments expressed as a 
ratio where the control values are taken as 1. *** P<0.0005 compared with the control VSMC 
and ### P<0.0005 to VSMC treated with IGF-1 alone. 
 
Figure 3. Pharmacological inhibitors of MAP Kinases (PD98059 (MEK1/2 inhibitor), 
UO126 (MEK1/2 inhibitor), SP600125 (JNK inhibitor) and SB203580 (p38 MAPK 
inhibitor)) did not inhibit IGF-1-induced HDAC5 phosphorylation in A10 VSMCs 
 
Confluent, serum-starved quiescent A10 VSMCs were pre-treated without (-) or with (10uM) 
PD98059 (MEK1/2 inhibitor) (A), UO126 (MEK1/2 inhibitor) (B), SP600125 (JNK inhibitor) 
(C) or SB203580 (p38 MAPK inhibitor) (D) for 30 minutes, followed by stimulation with 
50ng/ml IGF-1 for 5 minutes. Cell lysates were probed with pHDAC5 antibody, probed with 
either phospho-ERK1/2, phospho-p38 or phospho-JNK and also analyzed for protein loading 
using a total HDAC5 antibody. Bar diagrams represent the average quantification of HDAC5 
phosphorylation relative to total HDAC5. Values are the means ± SE of 3 independent 
experiments and expressed as a ratio where the control values are taken as 1.  *** P<0.0005 
compared with the control.  
 
Figure 4. Attenuation of IGF-1-induced HDAC5 phosphorylation by pharmacological 
inhibitors wortmannin (PI3-K inhibitor) and SC-66 (PKB inhibitor) in A10 VSMCs 
 
Confluent, serum-starved quiescent A-10 VSMCs were pre-treated with either wortmannin (PI3-
K inhibitor) (A) or SC-66 (PKB inhibitor) (B) for 30 minutes at indicated concentrations, 
followed by stimulation with 50ng/ml IGF-1 for 5 minutes. Cell lysates were probed with  
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pHDAC5 antibody, probed with pPKB and also analyzed for protein loading using a total 
HDAC5 antibody. Bar diagrams represent the average quantification of HDAC5 phosphorylation 
relative to total HDAC5. Values are the means ± SE of 3 independent experiments and expressed 
as a ratio where the control values are taken as 1. ***P<0.0005 compared with the control 
VSMC and ###P<0.0005 compared to VSMC treated with IGF-1 alone. C) shows 
immunofluorescence microscopy of pHDAC5 cellular localization in SC-66 and IGF-1 treated 
VSMCs. Cells growing on coverslips were fixed and stained with anti-phospho-HDAC5 
antibody (green signal). Nuclei were stained with DAPI (4´,6-diamidino-2-phenylindole) (blue 
signal). Merged pictures show the DAPI-stained image superimposed on the pHDAC5-stained 
image. Shown are representative images from 3 independent experiments. The images were 
taken using X-Cite series 120, TE2000-S fluorescence microscope.  
 
Figure 5. siRNA-induced silencing of PKB inhibits IGF-1-induced HDAC5 
phosphorylation in A10 VSMCs 
 
A10 VSMCs were transfected with 10nM PKB siRNA or 10 nM scrambled siRNA for 48 h prior 
to stimulation with 50ng/ml nM IGF-1 for 5 min. A) Cell lysates were immunoblotted with 
pHDAC5,  with PKB total or using a total HDAC5 antibody. Bar diagrams represent the average 
quantification of HDAC5 phosphorylation relative to total HDAC5. Values are the means ± SE 
of at least 3 independent experiments and are expressed as fold increase compared to the control 
value (CTL). ***P<0.0005 is considered statistically significant versus CTL. B) shows 
immunofluorescence microscopy of pHDAC5 cellular localization in PKB-silenced and IGF-1  
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treated VSMCs. Cells growing on coverslips were fixed and stained with anti-phospho-HDAC5 
antibody (green signal). Nuclei were stained with DAPI (4´,6-diamidino-2-phenylindole) (blue 
signal). Merged pictures show the DAPI-stained image superimposed on the pHDAC5-stained 
image. Shown are representative images from 3 independent experiments. The images were 
taken using X-Cite series 120, TE2000-S fluorescence microscope. 
 
Figure 6. Nuclear and cytoplasmic fractionation experiments illustrate that IGF-1-induced 
nuclear export of HDAC5 is mediated by PKB  
 
Confluent, serum-starved quiescent A-10 VSMCs were pre-treated with 10μM SC-66 for 30 
minutes, followed by stimulation with 50ng/ml IGF-1 for 5 minutes. Cell lysates were probed 
with total HDAC5 antibody (top panel), with β-tubulin to control for the purity of the cytosolic  
fraction (middle panel) and also analyzed with lamin B1 to control for the purity of the nuclear 
fraction (bottom panel). Bar diagrams represent the average quantification of total HDAC5 
relative to β-tubulin (cytosolic fraction) or total HDAC5 relative to lamin B1 (nuclear fraction) . 
Values are the means ± SE of 3 independent experiments and expressed as a ratio where the 
control values are taken as 1. ***P<0.0005 compared with the control VSMC and ###P<0.0005 
compared to VSMC treated with IGF-1 alone. 
 
Figure 7. ROS inhibitors Diphenyleneiodonium (DPI), Apocynin and N-Acetyl-Cysteine 
(NAC) inhibited IGF-1-induced HDAC5 and PKB phosphorylation in A10 VSMCs 
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Confluent, serum-starved quiescent A-10 VSMCs were pre-treated without (-) or with (10µM) 
DPI (A), without (-) or with (10µM) Apocynin (B) or without (-) or with (10µM) NAC (C) for 30 
minutes, followed by stimulation with 50ng/ml IGF-1 for 5 minutes. Cell lysates were probed 
with pHDAC5 antibody, with pPKB antibody and were also analyzed for protein loading using a 
total HDAC5 antibody. Bar diagrams represent the average quantification of HDAC5 
phosphorylation relative to total HDAC5. Values are the means ± SE of at 3 independent 
experiments and expressed as a ratio where the control values are taken as 1. *** P<0.0005, 
compared with the control VSMCs and ###P<0.0005 to VSMC treated with IGF-1 alone. 
 
Figure 8. siRNA-induced silencing of Nox4 inhibits IGF-1-induced HDAC5 
phosphorylation in A10 VSMCs 
 
A10 VSMCs were transfected with 10nM Nox4 siRNA or 10 nM control siRNA for 48 h prior to 
stimulation with 50ng/ml nM IGF-1 for 5 min. Cell lysates were immunoblotted with pHDAC5, 
total HDAC5, pPKB, total PKB and Nox4 antibodies. Bar diagrams represent the average 
quantification of HDAC5 phosphorylation relative to total HDAC5 or the quantification of PKB 
phosphorylation relative to total PKB. Values are the means ± SE of at least 3 independent 
experiments and are expressed as fold increase compared to the control value (CTL). 
***P<0.0005 is considered statistically significant versus CTL.  
 
Figure 9. Nuclear and cytoplasmic fractionation experiments illustrate that IGF-1-induced 
nuclear export of HDAC5 is ROS dependent 
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Confluent, serum-starved quiescent A-10 VSMCs were pre-treated with 10µM DPI for 30 
minutes, followed by stimulation with 50ng/ml IGF-1 for 5 minutes. Cell lysates were probed 
with total HDAC5 antibody (top panel), with β-tubulin to control for the purity of the cytosolic 
fraction (middle panel) and also analyzed with lamin B1 to control for the purity of the nuclear 
fraction (bottom panel). Bar diagrams represent the average quantification of total HDAC5 
relative to β-tubulin (cytosolic fraction) or total HDAC5 relative to lamin B1 (nuclear fraction). 
Values are the means ± SE of 3 independent experiments and expressed as a ratio where the 
control values are taken as 1. ***P<0.0005 compared with the control VSMC and ###P<0.0005 
compared to VSMC treated with IGF-1 alone. 
 
Figure 10: Schematic model of the involvement of PKB and ROS signaling in IGF-1-
induced HDAC5 phosphorylation and nuclear export in A10 VSMC 
 
In VSMCs, IGF-1 functions as a high-affinity ligand for IGF-1R in the cellular membrane, 
leading to autophosphorylation of IGF-1R and recruitment of the IRS adaptor proteins. The 
interaction of IGF-1R with the IRS proteins induces the activation of the class I phosphatidyl 
inositol 3’ kinase (PI3K). PI3K converts PIP2 into the lipid second messenger PIP3. PIP3 then 
activates PDK1 and PDK2, which go on to phosphorylate PKB at threonine 308 (Thr308) and 
serine 473 (Ser473), respectively. Activated PKB leads to the phosphorylation and export of 
HDAC5. Additionally, IGF-1R activation can lead to increased ROS generation via NAD(P)H 
oxidase activation, triggering the PKB and MAPK pathways. IGF-1-induced ROS generation 
increases IGF-1-induced HDAC5 phosphorylation and nuclear export. Contrastingly, activation 
of the MAPK pathway is not involved in IGF-1-induced HDAC5 phosphorylation.   
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The main feature of CVD is an increased vascular resistance due to blood vessel 
remodeling (2). Blood vessels are lined by VSMCs, which are highly specialized cells that 
regulate vascular tone and blood pressure (3). Abnormal migration, growth and proliferation of 
VSMCs are believed to be key events that contribute to structural remodeling of blood vessels 
and have been attributed to the pathogenesis of vascular diseases such as hypertension and 
atherosclerosis (3). A potential role of vasoactive peptides and growth factors, such as IGF-1, in 
inducing proliferation, hypertrophy, migration and differentiation of VSMCs has been 
demonstrated (5, 6, 7). IGF-1 binds to its receptor IGF-1R, a transmembrane tyrosine kinase that 
is greatly expressed in VSMCs, enabling IGF-1 to carry out its mitogenic effects (15). Once IGF-
1R is activated, two main signaling pathways are triggered giving rise to IGF-1's growth 
promoting properties. The first signaling cascade is the mitogen activated protein kinase 
(MAPK) pathway, which includes extracellular signal-regulated kinase 1/2 (ERK1/2), p38 
MAPK and c-jun-NH2 terminal kinase (JNK). ERK1/2, p38 MAPK and JNK have all been 
shown to participate in the cellular events that lead to aberrant VSMC growth and migration and 
hyperactivation of these signaling molecules is observed in various models of hypertension and 
atherosclerosis (15, 59, 60). The second well-known pathway triggered after IGF-1R activation 
in VSMCs is the phosphatidyl-inositol 3-kinase/protein kinase B (PI3-K/PKB) pathway (15,66). 
Additionally, IGF-1R activation can also lead to upregulated ROS generation via NAD(P)H 
Oxidase (Nox) activation, triggering the MAPK and PKB pathways and thus representing 
another important player in cardiovascular disease progression (15). The major isoforms of Nox 
expressed in VSMCs are Nox1 and Nox4 (183); however, Nox4-derived ROS has been shown to 
be required for IGF-1’s pathophysiological actions in the vasculature (184).   
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 In terms of HDAC5’s role in vascular disease, HDAC5 has been shown to be an 
important regulator of gene activity and has been linked to the pathogenesis of several 
cardiometabolic diseases including hypertension, atherosclerosis and diabetes (157). Studies 
have reported a role of angiotensin II (AngII) as well as platelet derived growth factor (PDGF) in 
mediating HDAC5 phosphorylation and activation in VSMCs (110, 111). In terms of the 
signaling pathway implicated in this process, it has been illustrated that CaMKII is capable of 
mediating AngII- and PDGF-dependent increases in HDAC5 phosphorylation (154, 156). 
Additionally, protein kinase D1 (PKD1), which is activated in a protein kinase C (PKC)-
dependent manner following AngII stimulation, has also been shown to mediate HDAC5 
phosphorylation (157). IGF-1, like AngII and PDGF, has been shown to promote VSMC 
migration and proliferation (15), thus contributing to the development of vascular pathologies. 
However, the effect of IGF-1 on HDAC5 phosphorylation and activation in VSMCs remains 
unexplored and the pathways that link IGF-1 to HDAC5 phosphorylation still need to be 
unraveled.  
 
In these studies, we examined the effect of IGF-1 on HDAC5 phosphorylation and 
nuclear export in VSMCs and determined the signaling pathways involved in this response. First, 
we demonstrated that IGF-1 stimulates HDAC5 phosphorylation in a time- and dose- dependent 
fashion. Then, we demonstrated that pharmacological blockade of the MAPK pathway with 
PD98059, UO126, SP600125 and SB203580 had no effect on HDAC5 phosphorylation, whereas 
inhibitors of the PI3K/ PKB pathways, wortmannin and SC-66, almost completely attenuated 
IGF-1-induced HDAC5 phosphorylation. In addition to immunoblotting data, these findings  
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were confirmed by immunofluorescence localization of phospho-HDAC5 and by siRNA- 
induced silencing of PKB. Our data also demonstrate that PKB-induced phosphorylation of 
HDAC5 contributed to its nuclear export, as shown through nuclear localization techniques. In 
addition, we demonstrated that pretreatment of A10 VSMCs with Diphenyleneiodonium (DPI) 
and apocynin, two NAD(P)H oxidase inhibitors, as well as the antioxidant N-Acetyl-Cysteine 
(NAC), resulted in an attenuation of IGF-1-induced phosphorylation of HDAC5 as well as PKB.  
We also demonstrated the involvement of ROS in IGF-1-mediated HDAC5 nuclear export 
through nuclear localization experiments using DPI. Finally, using siRNA-induced silencing of 
Nox4, we showed that IGF-1-induced HDAC5 phosphorylation is mediated through Nox4-
derived ROS.  To the best of our knowledge, the work presented here is the first to report an 
involvement of Nox4-derived ROS generation and PKB signaling in IGF-1-induced HDAC5 
phosphorylation and nuclear export in VSMCs.  
  
Taken together, our results demonstrate the involvement of the PI3-K/PKB pathway as 
well as Nox4-derived ROS generation as upstream regulators of HDAC5 phosphorylation in 
response to IGF-1. Since HDAC phosphorylation has been associated with enhanced migration 
and proliferation of VSMCs, it may be suggested that PKB-induced phosphorylation of HDAC5 
in VSMCs could constitute a potential mechanism to trigger a signaling program leading to 
vascular remodelling. In terms of future experiments, a role of IGF-1 in HDAC4 phosphorylation 
and activation has not been investigated. Therefore, in future studies, it would be interesting to 
examine the effect of IGF-1 on the phosphorylation and activation of HDAC4 in VSMCs and 
identify the signaling pathways involved in this process.                                                                                                                  
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The results presented here demonstrate for the first time that the PI3-K/PKB pathway as 
well as Nox4-derived ROS generation are required in mediating IGF-1-induced HDAC5 
phosphorylation and nuclear export in A10 VSMCs. These studies also demonstrated that the 
MAPK pathway was not involved in mediating IGF-1-induced HDAC5 phosphorylation in A10 
cells. These results were obtained using PD98059, U0126, SP600125 and SB203580, inhibitors 
of ERK1/2, MEK1, JNK and p38 MAPK, respectively, as well as wortmannin and SC-66, 
inhibitors of PI3-K and PKB, respectively, and using apocynin and DPI, inhibitors of NAD(P)H 
oxidase, and the antioxidant NAC.  
 
Studies have implicated IGF-1 in vascular remodeling through its promotion of VSMC 
proliferation, migration and hypertrophy. However, the precise mechanism by which IGF-1 
contributes to its deleterious responses in the vasculature remains to be determined. Our studies 
demonstrated that the PI3-K/PKB pathway and ROS generation act as upstream regulators of 
HDAC5 phosphorylation in response to IGF-1, contributing to exaggerated induction of genes 
involved in vascular remodelling.  
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